<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006745.pub3" GROUP_ID="LIVER" ID="737401052510542179" MERGED_FROM="" MODIFIED="2015-01-23 10:44:08 +0000" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="01" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2015-01-23 11:43:01 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2015-01-09 13:33:16 +0100" MODIFIED_BY="Dimitrinka Nikolova">Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma</TITLE>
<CONTACT>
<PERSON ID="BCF0913F82E26AA20144426C4B3B780B" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Konrad</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Schoppmeyer</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION/>
<EMAIL_1>konrad.schoppmeyer@euregio-klinik.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Internal Medicine</DEPARTMENT>
<ORGANISATION>Euregio-Klinik GmbH</ORGANISATION>
<ADDRESS_1>Albert-Schweitzer-Str. 10</ADDRESS_1>
<ADDRESS_2/>
<CITY>Nordhorn</CITY>
<ZIP>48529</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 5921 84 1660</PHONE_1>
<PHONE_2/>
<FAX_1>+49 5921 84 1664</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-01-23 11:43:01 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="35735DBF82E26AA200DA2AF314340255" MODIFIED="2015-01-23 11:40:54 +0100" MODIFIED_BY="Dimitrinka Nikolova" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sebastian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Weis</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>sebweis@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Gastroenterology and Rheumatology, Department of Internal Medicine, Neurology and Dermatology</DEPARTMENT>
<ORGANISATION>University of Leipzig Hospitals and Clinics, AöR</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Leipzig</CITY>
<ZIP>04103</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="53895579224828069557090904133706" MODIFIED="2015-01-23 11:41:00 +0100" MODIFIED_BY="Dimitrinka Nikolova" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Annegret</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Franke</LAST_NAME>
<SUFFIX/>
<POSITION>Biostatistician, PhD</POSITION>
<EMAIL_1>afranke@zks.uni-leipzig.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Trial Centre Leipzig</DEPARTMENT>
<ORGANISATION>University of Leipzig</ORGANISATION>
<ADDRESS_1>Haertelstrasse 16-18</ADDRESS_1>
<ADDRESS_2/>
<CITY>Leipzig</CITY>
<ZIP>04107</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="84187575208282353070120613115404" MODIFIED="2015-01-23 11:41:04 +0100" MODIFIED_BY="Dimitrinka Nikolova" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Thomas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Berg</LAST_NAME>
<SUFFIX/>
<POSITION>Professor at Universitätsklinikum Leipzig</POSITION>
<EMAIL_1>thomas.berg@medizin.uni-leipzig.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine, Neurology, and Dermatology</DEPARTMENT>
<ORGANISATION>Institute of Gastroenterology and Rheumatology</ORGANISATION>
<ADDRESS_1>Liebigstrasse 20</ADDRESS_1>
<ADDRESS_2/>
<CITY>Leipzig</CITY>
<ZIP>04103</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>03 41 / 9 71 23 30</PHONE_1>
<PHONE_2/>
<FAX_1>03 41 / 9 71 23 39</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="BCF0937282E26AA20144426C33405746" MODIFIED="2015-01-23 11:41:06 +0100" MODIFIED_BY="Dimitrinka Nikolova" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Joachim</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mössner</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Head of Department</POSITION>
<EMAIL_1>moej@medizin.uni-leipzig.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Gastroenterology and Rheumatology, Department of Internal Medicine, Neurology and Dermatology</DEPARTMENT>
<ORGANISATION>University of Leipzig</ORGANISATION>
<ADDRESS_1>Liebigstrasse 20</ADDRESS_1>
<ADDRESS_2/>
<CITY>Leipzig</CITY>
<ZIP>04103</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 341 97 109 ext: 12200</PHONE_1>
<PHONE_2/>
<FAX_1>+49 341 97 12209</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13998" MODIFIED="2015-01-23 11:41:08 +0100" MODIFIED_BY="Dimitrinka Nikolova" ROLE="AUTHOR">
<PREFIX>Professor</PREFIX>
<FIRST_NAME>Wolfgang E.</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fleig</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Medicine</POSITION>
<EMAIL_1>wolfgang.fleig@medizin.uni-leipzig.de</EMAIL_1>
<EMAIL_2>vorstand@uniklinik-leipzig.de</EMAIL_2>
<URL>www.uniklinik-leipzig.de</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>University of Leipzig Hospitals and Clinics, AöR</ORGANISATION>
<ADDRESS_1>Liebigstrasse 18</ADDRESS_1>
<ADDRESS_2/>
<CITY>Leipzig</CITY>
<ZIP>D-04103</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 (0341) 9715903</PHONE_1>
<PHONE_2>+49 (0170) 4576816</PHONE_2>
<FAX_1>+49 (0341) 9715909</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="BCF0913F82E26AA20144426C4B3B780B" MODIFIED="2015-01-23 11:41:11 +0100" MODIFIED_BY="Dimitrinka Nikolova" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Konrad</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Schoppmeyer</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION/>
<EMAIL_1>konrad.schoppmeyer@euregio-klinik.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Internal Medicine</DEPARTMENT>
<ORGANISATION>Euregio-Klinik GmbH</ORGANISATION>
<ADDRESS_1>Albert-Schweitzer-Str. 10</ADDRESS_1>
<ADDRESS_2/>
<CITY>Nordhorn</CITY>
<ZIP>48529</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 5921 84 1660</PHONE_1>
<PHONE_2/>
<FAX_1>+49 5921 84 1664</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-01-19 11:51:29 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="7" MONTH="7" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="7" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="11" MONTH="1" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-01-23 11:06:43 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-11-21 22:34:53 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="7" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>Literature search updated. A quasi-randomised study was removed from assessment of benefits (<LINK REF="STD-Huo-2003" TYPE="STUDY">Huo 2003</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-01-20 12:23:21 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="7" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>The conclusions have not changed as no new trials were added. This review will not be updated every second year unless new trials are published.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-01-23 11:06:43 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-01-23 11:06:43 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="21" MONTH="8" YEAR="2013"/>
<DESCRIPTION>
<P>Peer reviewers comments included. Risk of bias assessment changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-01-23 11:06:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="31" MONTH="10" YEAR="2012"/>
<DESCRIPTION>
<P>First author changed and new authors joined the review team.<BR/>Definitions of bias risk domains, used to assess the quality of trials, were up-dated.<BR/>A section on quality of evidence was added.<BR/>A study flow diagram was added.<BR/>The improved format of the RevMan software necessitated improvement of the structure of the review text.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-05-03 20:35:37 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-05-03 20:35:37 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-11-03 11:27:50 +0100" MODIFIED_BY="[Empty name]">
<NAME>Kompetenznetz Hepatitis (Hep-Net) Ostdeutschland</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-05-03 20:35:37 +0200" MODIFIED_BY="[Empty name]">
<NAME>Division of Gastroenterology, Rheumatology, Department of Internal Medicine, Dermatology and Neurology, University Hospital Leipzig</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY MODIFIED="2015-01-09 13:46:57 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2015-01-09 13:46:34 +0100" MODIFIED_BY="Dimitrinka Nikolova">Percutaneous ethanol injection for the treatment of early liver cancer</TITLE>
<SUMMARY_BODY MODIFIED="2015-01-09 13:46:57 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Background</B>
</P>
<P>Liver cancer (hepatocellular carcinoma) is the fifth most common cancer worldwide. In the majority of people, liver cancer is diagnosed at advanced stages of the disease and is mostly accompanied by liver cirrhosis. In high-income countries, about 30% of people present with the more favourable early liver cancer. For these people, percutaneous ablation techniques (destruction of the cancer cells by heat, cold, or chemical substances such as ethanol), surgical resection (removal of part of the liver), and liver transplantation (which is limited by organ donor shortage) are currently considered potentially curative treatments. We aimed to investigate the role of percutaneous injection of ethanol (PEI) and acetic acid (PAI) as compared with other treatments or no intervention for early liver cancer. This review excluded the effects of radiofrequency thermal ablation as this has been already addressed in a previous Cochrane Hepato-Biliary Group systematic review.</P>
<P>
<B>Study characteristics</B>
</P>
<P>The review authors searched the medical literature in order to clarify the role of PEI and PAI for the treatment of liver cancer and to compare their benefits and harms with no treatment, with placebo (a pretend treatment), or with other treatments (such as laser, cryoablation, or microwave ablation; hepatic resection; and liver transplantation). We collected and analysed data from randomised clinical trials (where people were allocated at random to one of two or more treatments groups) of people with liver cancer who were able to receive PEI or PAI. Evidence is current to July 2014.</P>
<P>
<B>Key results and quality of evidence </B>
</P>
<P>The review authors only identified three randomised trials with 261 participants. The risk of bias was low in one and high in two trials. We found two trials that compared PEI versus PAI and one trial that compared PEI versus surgery. We found no trials that compared PEI or PAI versus sham (pretend) intervention, best supportive care, cryotherapy, laser-induced thermotherapy, or high-frequency ultrasound. We found no randomised trials that compared PAI versus surgery.</P>
<P>The review authors found low-quality evidence suggesting that PEI yielded the same result as PAI regarding overall survival (the length of time that the person remains alive) and recurrence-free survival (time that the person remains free of cancer). We calculated the number of participants that would be required to judge a relative risk reduction (relative risk is a comparison of the risk of an event happening for one treatment group compared with another treatment group) for survival of 20%. We found that for the comparisons PEI versus PAI, the number of participants was too low to reach valid conclusions. In both groups, participants reported the occurrence of mild side effects such as transient fever, flushing, and local pain. Based on one randomised trial with high risk of bias, there was very low quality evidence that surgical resection does not seem to be superior to PEI in people with early liver cancer. Of note, no severe side effects occurred in people treated with PEI while there were three postoperative deaths in people treated surgically. Again, too few participants were randomised to claim or reject important differences.</P>
<P>There is a need for more randomised clinical trials assessing interventions for people with early-stage liver cancer. Such trials should be conducted with low risks of bias (systematic errors, that is overestimation of benefits and underestimation of harms) and of play of chance (random errors, that is errors due to too few participants and too few outcomes).</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-01-19 11:44:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ABS_BACKGROUND MODIFIED="2015-01-09 13:33:29 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Hepatocellular carcinoma (HCC) is the fifth most common global cancer. When HCC is diagnosed early, interventions such as percutaneous ethanol injection (PEI), percutaneous acetic acid injection (PAI), or radiofrequency (thermal) ablation (RF(T)A) may have curative potential and represent less invasive alternatives to surgery.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-01-09 13:44:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>To evaluate the beneficial and harmful effects of PEI or PAI in adults with early HCC defined according to the Milan criteria, that is, one cancer nodule up to 5 cm in diameter or up to three cancer nodules up to 3 cm in diameter compared with no intervention, sham intervention, each other, other percutaneous interventions, or surgery.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-01-09 13:44:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched the Cochrane Hepato-Biliary Group Controlled Trials Register (July 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 6), MEDLINE (1946 to July 2014), EMBASE (1976 to July 2014), and Science Citation Index Expanded (1900 to July 2014). We handsearched meeting abstracts of six oncological and hepatological societies and references of articles to July 2014. We contacted researchers in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-01-09 13:45:44 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We considered randomised clinical trials comparing PEI or PAI versus no intervention, sham intervention, each other, other percutaneous interventions, or surgery for the treatment of early HCC regardless of blinding, publication status, or language. We excluded studies comparing RFA or combination of different interventions as such interventions have been or will be addressed in other Cochrane Hepato-Biliary Group systematic reviews.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-01-09 13:45:53 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Two review authors independently selected trials for inclusion, and extracted and analysed data. We calculated the hazard ratios (HR) for median overall survival and recurrence-free survival using the Cox regression model with Parmar's method. We reported type and number of adverse events descriptively. We assessed risk of bias by The Cochrane Collaboration domains to reduce systematic errors and risk of play of chance by trial sequential analysis to reduce random errors. We assessed the methodological quality with GRADE.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-01-19 11:44:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We identified three randomised trials with 261 participants for inclusion. The risk of bias was low in one and high in two trials.</P>
<P>Two of the randomised trials compared PEI versus PAI; we included 185 participants in the analysis. The overall survival (HR 1.47; 95% confidence interval (CI) 0.68 to 3.19) and recurrence-free survival (HR 1.42; 95% CI 0.68 to 2.94) were not statistically significantly different between the intervention groups of the two trials. Trial sequential analysis for the comparison PEI versus PAI including two trials revealed that the number of participants that were included in the trials were insufficient in order to judge a relative risk reduction of 20%. Data on the duration of hospital stay were available from one trial for the comparison PEI versus PAI showing a significantly shorter hospital stay for the participants treated with PEI (mean 1.7 days; range 2 to 3 days) versus PAI (mean 2.2 days; range 2 to 5 days). Quality of life was not reported. There were only mild adverse events in participants treated with either PEI or PAI such as transient fever, flushing, and local pain.</P>
<P>One randomised trial compared PEI versus surgery; we included 76 participants in the analyses. There was no significant difference in the overall survival (HR 1.57; 95% CI 0.53 to 4.61) and recurrence-free survival (HR 1.35; 95% CI 0.69 to 2.63). No serious adverse events were reported in the PEI group while three postoperative deaths occurred in the surgery group.</P>
<P>In addition to the three randomised trials, we identified one quasi-randomised study comparing PEI versus PAI. Due to methodological flaws of the study, we extracted only the data on adverse events and presented them in a narrative way.</P>
<P>We found no randomised trials that compared PEI or PAI versus no intervention, best supportive care, sham intervention, or other percutaneous local ablative therapies excluding RFTA. We found also no randomised clinical trials that compared PAI versus other interventional treatments or surgery. We identified two ongoing randomised clinical trials. One of these two trials compares PEI versus surgery and the other PEI versus transarterial chemoembolization. To date, it is unclear whether the trials will be eligible for inclusion in this meta-analysis as the data are not yet available. This review will not be updated until new randomised clinical trials are published and can be used for analysis.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-01-09 13:46:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>PEI versus PAI did not differ significantly regarding benefits and harms in people with early HCC, but the two included trials had only a limited number of participants and one trial was judged a high risk of bias. Thus, the current evidence precludes us from making any firm conclusions.</P>
<P>There was also insufficient evidence to determine whether PEI versus surgery (segmental liver resection) was more effective, because conclusions were based on a single randomised trial. While some data from this single trial suggested that PEI was safer, the high risk of bias and the lack of any confirmatory evidence make a reliable assessment impossible.</P>
<P>We found no trials assessing PEI or PAI versus no intervention, best supportive care, or sham intervention.</P>
<P>There is a need for more randomised clinical trials assessing interventions for people with early stage HCC. Such trials should be conducted with low risks of systematic errors and random errors.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<BACKGROUND MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CONDITION MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="3">Epidemiology and risk factors</HEADING>
<P>Hepatocellular carcinoma (HCC) currently ranks fifth in global cancer incidence and mortality (<LINK REF="REF-Parkin-2001" TYPE="REFERENCE">Parkin 2001</LINK>; <LINK REF="REF-Parkin-2005" TYPE="REFERENCE">Parkin 2005</LINK>). Highest occurrences of HCC are found in Eastern Asia and Middle Africa. In addition, one trial suggested a rising incidence of HCC in high-income countries (<LINK REF="REF-El-Serag-1999" TYPE="REFERENCE">El Serag 1999</LINK>). Due to the large pool of hepatitis C virus (HCV) in these countries, the rise in cirrhosis and HCC incidence is expected to continue over the next decades (<LINK REF="REF-El-Serag-2004a" TYPE="REFERENCE">El Serag 2004a</LINK>). Overall, 75% to 80% of primary liver cancers are attributable to persistent viral infections with either hepatitis B virus (HBV) (50% to 55%) or HCV (25% to 30%). High consumption of alcohol, non-alcoholic fatty liver disease, cumulative amount of aflatoxins in the liver over time, haemochromatosis, and alpha-1-antitrypsin are further risk factors for HCC development (<LINK REF="REF-S_x00f8_rensen-2003" TYPE="REFERENCE">Sørensen 2003</LINK>; <LINK REF="REF-Bosch-2004" TYPE="REFERENCE">Bosch 2004</LINK>; <LINK REF="REF-EASL_x002d_EORTC-2012" TYPE="REFERENCE">EASL-EORTC 2012</LINK>). Smoking is an independent and a dose-related risk factor contributing to HCC (<LINK REF="REF-Lee-2009" TYPE="REFERENCE">Lee 2009</LINK>). Associations of primary liver cancer with diabetes (<LINK REF="REF-El-Serag-2004b" TYPE="REFERENCE">El Serag 2004b</LINK>), obesity (<LINK REF="REF-Calle-2003" TYPE="REFERENCE">Calle 2003</LINK>), and syndromes related to insulin resistance are subject of ongoing research activity, but their impacts are currently unclear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Prognosis</HEADING>
<P>Overall, liver cancer carries high mortality. In Europe and the USA, five-year survival occurrences are below 10% (<LINK REF="REF-Coleman-2003" TYPE="REFERENCE">Coleman 2003</LINK>; <LINK REF="REF-Ries-2007" TYPE="REFERENCE">Ries 2007</LINK>). Percutaneous techniques, surgical resection, and liver transplantation are currently classified as potentially curative treatments (<LINK REF="REF-Bruix-2001" TYPE="REFERENCE">Bruix 2001</LINK>). In high-income countries, only about 30% of people present with early HCC and are candidates for these potentially radical treatments.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Diagnosis</HEADING>
<P>Due to the neovascularity of HCC and the ability to equate neovascularity with contrast enhancement on rapid-sequence cross-sectional imaging studies, the accurate diagnosis of HCC lesions that are bigger than 2 cm in diameter can be made non-invasively in people with cirrhosis. According to the European Association for the Study of the Liver (<LINK REF="REF-Bruix-2001" TYPE="REFERENCE">Bruix 2001</LINK>), non-invasive diagnostic criteria for people with cirrhosis and HCC are:</P>
<UL>
<LI>radiological criteria: two coincident imaging techniques (the following imaging techniques are considered: ultrasonography, spiral computer tomography, magnetic resonance imaging, and angiography);</LI>
<LI>combined criteria: one imaging technique associated with alpha-fetoprotein: focal lesion bigger than 2 cm with arterial hypervascularity and alpha-fetoprotein levels higher than 400 ng/mL.</LI>
</UL>
<P>Image-guided biopsies are common practice in case of indeterminate radiological findings (i.e., discordant findings on different imaging techniques) and lesions between 1 cm and 2 cm in diameter (<LINK REF="REF-Takamori-2000" TYPE="REFERENCE">Takamori 2000</LINK>; <LINK REF="REF-Serst_x00e9_-2012" TYPE="REFERENCE">Sersté 2012</LINK>). If a curative surgical treatment is still possible, taking biopsies is frequently avoided due to its risks, especially bleeding and tumour cell dissemination.</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2015-01-09 13:47:36 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<I>Surgical resection</I> of HCC is often not feasible due to the impairment of liver function associated with the prevalent underlying cirrhosis. HCC recurrences after surgical resection are about 50% at three years and 70% after five years (<LINK REF="REF-Arii-2000" TYPE="REFERENCE">Arii 2000</LINK>; <LINK REF="REF-Bismuth-2000" TYPE="REFERENCE">Bismuth 2000</LINK>; <LINK REF="REF-Llovet--2000" TYPE="REFERENCE">Llovet 2000</LINK>; <LINK REF="REF-Torzilli-2013" TYPE="REFERENCE">Torzilli 2013</LINK>).</P>
<P>
<I>Percutaneous local ablative therapies</I> are currently considered as the preferred option for early unresectable HCC. All local ablative techniques have the advantage of preserving the uninvolved liver parenchyma and avoid the morbidity and mortality of major hepatic surgery (<LINK REF="REF-Bruix-2001" TYPE="REFERENCE">Bruix 2001</LINK>). <I>Percutaneous ethanol injection (PEI)</I> causes dehydration and necrosis of tumour cells (<LINK REF="REF-EASL_x002d_EORTC-2012" TYPE="REFERENCE">EASL-EORTC 2012</LINK>), accompanied by small vessel thrombosis, leading to tumour ischaemia and destruction (<LINK REF="REF-Livraghi-1995" TYPE="REFERENCE">Livraghi 1995</LINK>). PEI is usually carried out under ultrasound guidance with repeated injections of ethanol on separate days. Best results for PEI are achieved in single HCC lesions less than 3 cm in diameter, in which complete remission of about 70% of cancers can be expected. In larger or multinodular cancers (or both), total necrosis is less likely with PEI (<LINK REF="REF-Livraghi-1995" TYPE="REFERENCE">Livraghi 1995</LINK>; <LINK REF="REF-Lencioni-1997" TYPE="REFERENCE">Lencioni 1997</LINK>). <I>Percutaneous acetic acid injection (PAI)</I> has been used as an alternative for PEI (<LINK REF="REF-Ohnishi-1996a" TYPE="REFERENCE">Ohnishi 1996a</LINK>; <LINK REF="REF-Ohnishi-1998a" TYPE="REFERENCE">Ohnishi 1998a</LINK>). Contraindications for PEI and PAI are cirrhosis with poor liver function (Child C cirrhosis), complete portal vein thrombosis, and massive ascites. <I>Radiofrequency thermal ablation (RFTA)</I> makes use of frictional heat to induce cell death from coagulation necrosis. The major advantages of RFTA are the lower number of sessions necessary for tumour destruction compared to PEI or PAI, and the prolonged overall and recurrence-free survival (<LINK REF="REF-Lencioni-2003" TYPE="REFERENCE">Lencioni 2003</LINK>; <LINK REF="REF-Galandi-2004" TYPE="REFERENCE">Galandi 2004</LINK>; <LINK REF="REF-Lin-2004" TYPE="REFERENCE">Lin 2004</LINK>; <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>; <LINK REF="REF-Shiina-2005" TYPE="REFERENCE">Shiina 2005</LINK>; <LINK REF="REF-Brunello-2008" TYPE="REFERENCE">Brunello 2008</LINK>). Further<I> percutaneous techniques</I>, such as cryoablation or interstitial laser photocoagulation, are under clinical investigation.</P>
<P>
<I>Liver transplantation </I>is an alternative approach for selected people with small HCC. However, the beneficial removal of liver cirrhosis as a predisposing factor for HCC is often counterbalanced by progression of the tumour while the patient is waiting for a new organ. Organ shortage is a major factor limiting the availability of this procedure.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-01-09 13:47:36 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>See <LINK TAG="INTERVENTION" TYPE="SECTION">Description of the intervention</LINK>.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-01-09 13:47:36 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Percutaneous techniques are used with increasing frequency as a bridge to liver transplantation and with a curative intention for small HCC. The present systematic review is an update of our previous review published in 2009 (<LINK REF="REF-Schoppmeyer-2009" TYPE="REFERENCE">Schoppmeyer 2009</LINK>). We identified no other meta-analyses or systematic reviews on PEI or PAI for people with early HCC. The aim of this new review was to investigate whether new trials have been published since the first review and whether the evidence has been improved or changed.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-01-09 13:47:36 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>To evaluate the beneficial and harmful effects of PEI or PAI in adults with early HCC defined according to the Milan criteria, that is, one cancer nodule up to 5 cm in diameter or up to three cancer nodules up to 3 cm in diameter compared with no intervention, sham intervention, each other, other percutaneous interventions, or surgery.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SELECTION_CRITERIA MODIFIED="2015-01-09 13:48:19 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_STUDIES MODIFIED="2015-01-09 13:47:55 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trials on percutaneous local ablative therapies, irrespective of blinding, publication status, or language. We included abstracts or unpublished data if sufficient information on study design, characteristics of participants, interventions, and outcomes was available and if full information was confirmed by contact with the study authors. We considered non-randomised studies that were retrieved with the searches for randomised trials for harm data only.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-01-09 13:48:10 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>People with early HCC, defined according to the Milan criteria as "one nodule up to five cm in diameter or up to three nodules up to three cm in diameter" (<LINK REF="REF-Mazzaferro-1996" TYPE="REFERENCE">Mazzaferro 1996</LINK>). The diagnosis of HCC may have been established either by histology or cytology, or a combination of radiological criteria and alpha-fetoprotein as described in the <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK> section.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-01-09 13:48:10 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We assessed the following comparisons.<BR/>
</P>
<UL>
<LI>Percutaneous local ablative therapies (PEI or PAI) versus no intervention or best supportive care or sham intervention.</LI>
<LI>PEI versus other percutaneous local ablative therapies excluding RFTA.</LI>
<LI>PAI versus other percutaneous local ablative therapies excluding RFTA.</LI>
<LI>Percutaneous local ablative therapies (PEI or PAI) versus surgery.</LI>
</UL>
<P>We did not consider in this review studies using combinations of percutaneous treatments and other approaches, such as transarterial chemoembolisation, RFTA, surgery, and cryotherapy, which are dealt with in other Cochrane Hepato-Biliary Group reviews (<LINK REF="REF-Galandi-2004" TYPE="REFERENCE">Galandi 2004</LINK>; <LINK REF="REF-Abrishami-2008" TYPE="REFERENCE">Abrishami 2008</LINK>; <LINK REF="REF-Awad-2009" TYPE="REFERENCE">Awad 2009</LINK>; <LINK REF="REF-Oliveri-2011" TYPE="REFERENCE">Oliveri 2011</LINK>; <LINK REF="REF-Weis-2013" TYPE="REFERENCE">Weis 2013</LINK>). We did not consider liver transplantation as a type of intervention in this review since organ shortage limits the availability of this treatment and living donor transplantation has inherent ethical issues that prevents it from being a treatment option in randomised clinical trials.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-01-09 13:48:19 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<UL>
<LI>Overall survival.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Recurrence-free survival.</LI>
<LI>Number and type of adverse events. We defined adverse event as any untoward medical occurrence that did not necessarily have a causal relationship with the treatment, but did result in a dose reduction, discontinuation of treatment, or registration of the event as an adverse event (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>).</LI>
<LI>Duration of hospital stay.</LI>
<LI>Quality of life according to a validated questionnaire (<LINK REF="REF-Heffernan-2002" TYPE="REFERENCE">Heffernan 2002</LINK>).</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-01-09 13:48:19 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ELECTRONIC_SEARCHES MODIFIED="2015-01-09 13:48:19 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched the Cochrane Hepato-Biliary Group Controlled Trials Register (July 2014) (<LINK REF="REF-Gluud-2014" TYPE="REFERENCE">Gluud 2014</LINK>), the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 6), MEDLINE (1946 to July 2014), EMBASE (1980 to July 2014), and Science Citation Index Expanded (1900 to July 2014) (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>). <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> shows the search strategies with the time spans of the searches.</P>
<P>We searched the <A HREF="http://ClinicalTrials.gov">ClinicalTrials.gov</A> database using the terms "percutaneous ethanol injection", "percutaneous acetic acid injection", "PEI", and "PAI".</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-01-09 13:48:19 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We handsearched meeting abstracts from the American Society for Clinical Oncology (ASCO) (1990 to 2014), the European Society of Medical Oncology (ESMO) (1990 to 2014, published in the <I>Annals of Oncology</I>), the European Council for Clinical Oncology (ECCO) (1990 to 2014, published in the <I>European Journal of Cancer</I>); the American Association for the Study of the Liver (AASLD) (1991 to 2014, published in <I>Hepatology</I>); the European Association for the Study of the Liver (EASL) (1985 to 2014, published in the <I>Journal of Hepatology</I>), and the Asian Pacific Association for the Study of the Liver (APASL) (1990 to 2014, published in the <I>Journal of Gastroenterology and Hepatology</I>).</P>
<P>We identified further trials from the reference lists of the identified studies, by contacting investigators as well as national and international experts, and by writing to companies selling equipment for percutaneous local ablative therapies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_SELECTION MODIFIED="2015-01-09 13:48:29 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Two review authors (KS, SW) independently scanned the title, abstract, and keywords of every record retrieved. Publications were taken into account for further assessment if the information given suggested that the trial might meet our inclusion criteria. We then listed these publications under included studies or excluded studies. We provided the reason for exclusion of excluded studies.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-01-09 13:48:29 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Two review authors independently extracted details of trial population, interventions, and outcomes using a standardised data extraction form. We resolved differences in data extraction by consensus with a third review author. We contacted all trial authors, as questions arose in all included trials. The data extraction form included the following items.<BR/>
</P>
<UL>
<LI>General information: title, authors, source, contact address, country, publication status, language, year of publication, and trial sponsors.</LI>
<LI>Trial characteristics: design, duration of follow-up, number of participants randomised.</LI>
<LI>Participants: inclusion and exclusion criteria, sample size, baseline characteristics (Child score, aetiology of liver cirrhosis: unknown, HBV or HCV, others), withdrawals and losses to follow-up, method of diagnosis of HCC.</LI>
<LI>Interventions: category of percutaneous therapy (percutaneous injection: ethanol, acetic acid; percutaneous thermal ablation, percutaneous cryoablation) and comparator intervention (sham, best supportive care, no intervention, other percutaneous intervention, surgery).</LI>
<LI>Outcomes: primary outcome: survival time, hazard ratios (HR) and their 95% confidence intervals (CI), log rank Chi<SUP>2</SUP>, log rank P values, number of events, number of participants per group, median survival in people with HCC. Secondary outcomes: recurrence-free survival, number and type of adverse events, duration of hospital stay, and quality of life.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-01-09 13:49:09 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="4">Quality assessment of trials</HEADING>
<P>Because of the risk of overestimation of treatment effects in randomised clinical trials with high risk of bias (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <LINK REF="REF-Lundh-2012" TYPE="REFERENCE">Lundh 2012</LINK>; <LINK REF="REF-Savovic-2012a" TYPE="REFERENCE">Savovic 2012a</LINK>; <LINK REF="REF-Savovic-2012b" TYPE="REFERENCE">Savovic 2012b</LINK>), we assessed the impact of methodological quality according to the following criteria.</P>
<SUBSECTION>
<HEADING LEVEL="5">Allocation sequence generation</HEADING>
<UL>
<LI>Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent research assistant not otherwise involved in the trial.</LI>
<LI>Uncertain risk of bias: the method of sequence generation was not specified.</LI>
<LI>High risk of bias: the sequence generation method was not random.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Allocation concealment</HEADING>
<UL>
<LI>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g., if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes).</LI>
<LI>Uncertain risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.</LI>
<LI>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blinding of participants, personnel, and outcome assessors</HEADING>
<UL>
<LI>Low risk of bias: blinding was performed adequately, or the assessment of outcomes was not likely to be influenced by lack of blinding.</LI>
<LI>Uncertain risk of bias: there was insufficient information to assess whether blinding was likely to induce bias on the results.</LI>
<LI>High risk of bias: no blinding or incomplete blinding, and the assessment of outcomes were likely to be influenced by lack of blinding.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Incomplete outcome data</HEADING>
<UL>
<LI>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, have been employed to handle missing data.</LI>
<LI>Uncertain risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.</LI>
<LI>High risk of bias: the results were likely to be biased due to missing data.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Selective outcome reporting</HEADING>
<UL>
<LI>Low risk of bias: all outcomes were pre-defined (e.g., in a published protocol) and reported, or all clinically relevant and reasonably expected outcomes were reported. We considered the following outcome measures as clinically relevant: survival, recurrence-free survival, and adverse events.</LI>
<LI>Uncertain risk of bias: it was unclear whether all pre-defined and clinically relevant and reasonably expected outcomes were reported.</LI>
<LI>High risk of bias: one or more clinically relevant and reasonably expected outcomes were not reported, and data on these outcomes were likely to have been recorded.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Academic bias</HEADING>
<UL>
<LI>Low risk of bias: if authors had not performed a trial on the same topic before.</LI>
<LI>Uncertain risk of bias: if it could not be made clear if one of the authors was involved in a trial on the same topic before.</LI>
<LI>High risk of bias: if authors had performed a trial on the same topic before.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other risks of bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appeared free of other components that could put it at risk of bias.</LI>
<LI>Uncertain risk of bias: it was unclear whether the trial was free of other components that could put it at risk of bias.</LI>
<LI>High risk of bias: there were other factors in the trial that could put it at risk of bias (e.g. for-profit involvement).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Overall risk of bias assessment</HEADING>
<P>We considered a trial to have low risk of bias if all of the above specified domains of risk assessment were considered low risk of bias. We considered a trial with high risk of bias if one or more of the specific domains of risk assessment were unclear or with high risk of bias.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-01-09 13:49:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We calculated the HR and 95% CI for median overall survival and recurrence-free survival using the Cox regression model with Parmar's method (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>). We reported type and number of adverse events descriptively.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-01-09 13:49:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included trials with three or more treatment groups if pair-wise comparison of a single intervention to a percutaneous local ablative therapy was possible and if inclusion criteria of both groups fulfilled our inclusion criteria. In order to exclude analysis bias by multiple counting of the shared intervention group, we split the shared intervention group into a corresponding number of subgroups with smaller sample size. We analysed and included each pair-wise comparison separately. We measured two survival outcomes. We analysed recurrence-free survival and overall survival separately.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-01-09 13:49:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>In the case of missing data, we contacted trial authors and asked them to provide us with the missing data. We assessed missing data in the judgement of selective and incomplete reporting bias. We obtained HR and standard deviations or Kaplan Meier survival plots for the survival outcomes if the required data (HR and 95% CI) were not available from the original publications.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-01-09 13:49:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We performed Cochrane's Q-test (with a significance threshold of P value = 0.1) in order to look for statistical heterogeneity between the trials. In addition, we calculated the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). We considered the bias risk of the trials a potential source of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-01-09 13:49:22 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We planned to prepare a funnel plot if we included 10 or more trials for visual assessment of whether treatment estimates were associated with trial size. To detect bias, we planned to use a method that has a good trade-off in sensitivity and specificity for the trials included in our review (<LINK REF="REF-Begg-1994" TYPE="REFERENCE">Begg 1994</LINK>; <LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>; <LINK REF="REF-Macaskill-2001" TYPE="REFERENCE">Macaskill 2001</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="3">Meta-analysis</HEADING>
<P>We performed the meta-analyses according to the recommendations of The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), and the Cochrane Hepato-Biliary Group Module (<LINK REF="REF-Gluud-2014" TYPE="REFERENCE">Gluud 2014</LINK>). We extracted HRs as relevant effect measures for survival time and recurrence-free survival with 95% CI. We estimated HR (under some assumptions) from log rank Chi<SUP>2</SUP>, from log rank P values, from observed to expected event ratios, or Kaplan-Meier curves with participants at a given risk, using methods presented by <LINK REF="REF-Machin-1997" TYPE="REFERENCE">Machin 1997</LINK> (<LINK REF="REF-Machin-1997" TYPE="REFERENCE">Machin 1997</LINK>) and <LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK> (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>) We conducted random-effects model and fixed-effect model meta-analyses and reported both results if they differed. We performed statistical analyses with Review Manager 5 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trial sequential analysis</HEADING>
<P>We applied trial sequential analysis (<LINK REF="REF-CTU-2011" TYPE="REFERENCE">CTU 2011</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>) because cumulative meta-analyses are at risk of producing random errors due to sparse data and repetitive testing of the accumulating data (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>). To minimise random errors, we calculated the required information size (i.e., the number of participants needed in a meta-analysis to detect or reject a certain intervention effect) (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>). The required information size calculation should also account for the diversity present in the meta-analysis (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). In our meta-analysis, the required information size was based on the event proportion in the control group; assumption of a plausible relative risk reduction of 20%; a risk of type I error of 5%; a risk of type II error of 20%; and the assumed diversity of the meta-analysis (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>).</P>
<P>The underlying assumption of trial sequential analysis is that testing for significance may be performed each time a new trial is added to a meta-analysis. We added the trials according to the year of publication, and if more than one trial was published in one year, we added trials alphabetically according to the last name of the first author. On the basis of the diversity-adjusted required information size, we constructed trial sequential monitoring boundaries (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>). These boundaries determine the statistical inference one may draw regarding the cumulative meta-analysis that has not reached the required information size. If the trial sequential monitoring boundary for benefit or harm is crossed by the cumulative Z-curve before the required information size is reached, firm evidence may perhaps be established and further trials may turn out to be superfluous. In contrast, if the boundary is not surpassed, it is most probably necessary to continue doing trials in order to detect or reject a certain intervention effect if the trial sequential monitoring boundaries for futility are not crossed. If the latter case, futility is declared (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>).</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-01-09 13:49:30 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>In the case of sufficient data, we had planned subgroup analyses in order to make a distinction between the aetiology of liver cirrhosis and the diagnosis of HCC.</P>
<UL>
<LI>Trials with low risk of bias compared to trials with high risk of bias.</LI>
<LI>Cirrhosis of unknown cause compared to cirrhosis caused by HBV and compared to cirrhosis caused by HCV.</LI>
<LI>People with HCC diagnosed by histology or cytology compared to people with HCC diagnosed by radiological or combined criteria.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-01-09 13:49:30 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We planned to conduct 'best-worst' and 'worst-best' case scenario analyses to test for sensitivity to attrition bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>; <LINK REF="REF-Gluud-2014" TYPE="REFERENCE">Gluud 2014</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' table</HEADING>
<P>We summarised the evidence in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> using GRADEpro (<A HREF="http://ims.cochrane.org/revman/other-resources/gradepro">ims.cochrane.org/revman/other-resources/gradepro</A>) in order to present the findings of the review in a simple tabular format (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), and using the GRADE classification to assess the quality of the evidence (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>).</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_DESCRIPTION MODIFIED="2015-01-09 13:49:39 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We identified 2379 publications by electronic database searches.</P>
<SEARCH_RESULTS MODIFIED="2015-01-09 13:49:39 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Electronic literature searches revealed 57 hits in the Cochrane Hepato-Biliary Group Controlled Trials Register, 300 hits in the Cochrane Central Register of Controlled Trials (CENTRAL), 563 hits in MEDLINE, 747 hits in EMBASE, and 712 hits in Science Citation Index Expanded. <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> shows the search strategies. The handsearches of meeting abstracts found no additional studies. We found two new trials in the US trial registry (<A HREF="http://www.clinicaltrial.gov">www.clinicaltrial.gov</A>) that were just completed and from which results or data were not yet available (<LINK REF="STD-NCT00357422" TYPE="STUDY">NCT00357422</LINK>; <LINK REF="STD-NCT00357474" TYPE="STUDY">NCT00357474</LINK>). We classified them as ongoing trials.<BR/>
<BR/>Two review authors (KS and SW) independently screened the results of the literature searches and found 41 studies suitable for further analysis; we excluded 23 of these due to duplication. We retrieved the entire manuscripts of the remaining 18 studies. Of these, we excluded 13 studies. Four publications on trials fulfilled the inclusion criteria, of which one was published twice (<LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>). We excluded one quasi-randomised study (<LINK REF="STD-Huo-2003" TYPE="STUDY">Huo 2003</LINK>) (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), which was initially considered for a subgroup analysis in the first published version of this review (<LINK REF="REF-Schoppmeyer-2009" TYPE="REFERENCE">Schoppmeyer 2009</LINK>), from the primary analysis in the present updated review as trials with inadequate randomisation methodology tend to increase the risk of false-positive findings (<LINK REF="REF-Gluud-2005" TYPE="REFERENCE">Gluud 2005</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <LINK REF="REF-Savovic-2012a" TYPE="REFERENCE">Savovic 2012a</LINK>; <LINK REF="REF-Savovic-2012b" TYPE="REFERENCE">Savovic 2012b</LINK>). We did not include one trial due to insufficient available information and classified it as 'study awaiting classification' (<LINK REF="STD-Tsai-2008" TYPE="STUDY">Tsai 2008</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-01-09 13:49:39 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included three randomised trials presented in four publications in this systematic review with 261 participants. One of these three trials compared PEI versus PAI and was published twice (<LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>). The 'three' arm trial compared RFA versus PEI versus PAI (<LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>). We excluded 62 participants who had received RFA from the analysis (<LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>). Ninety-one participants in both trials were allocated to PEI versus 94 participants to PAI (<LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>; <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>) and 182/185 participants had underlying liver cirrhosis. The third trial compared 76 people with early HCC, of whom 60 had underlying liver cirrhosis, who received PEI versus surgical resection (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>). One study is awaiting classification as there are currently insufficient data available to judge whether it can be included (<LINK REF="STD-Tsai-2008" TYPE="STUDY">Tsai 2008</LINK>). We contacted the authors twice but they did not reply.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-01-09 13:49:39 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We excluded 13 studies: one was published as a meeting abstract and it did not contain sufficient data. We were unsuccessful in contacting the corresponding author (<LINK REF="STD-Bottelli-1997" TYPE="STUDY">Bottelli 1997</LINK>). Five studies were not adequately randomised (<LINK REF="STD-Orlando-1997" TYPE="STUDY">Orlando 1997</LINK>; <LINK REF="STD-Huo-2002" TYPE="STUDY">Huo 2002</LINK>; <LINK REF="STD-Huo-2003" TYPE="STUDY">Huo 2003</LINK>; <LINK REF="STD-Huo-2004" TYPE="STUDY">Huo 2004</LINK>; <LINK REF="STD-Dettmer-2006" TYPE="STUDY">Dettmer 2006</LINK>). One of them (<LINK REF="STD-Dettmer-2006" TYPE="STUDY">Dettmer 2006</LINK>), as well as two additional studies (<LINK REF="STD-Sarin-1994" TYPE="STUDY">Sarin 1994</LINK>; <LINK REF="STD-Bruix-1998" TYPE="STUDY">Bruix 1998</LINK>), investigated large instead of early HCC. Five studies were case series or retrospective studies (<LINK REF="STD-Danila-2009" TYPE="STUDY">Danila 2009</LINK>; <LINK REF="STD-Kirikoshi-2009" TYPE="STUDY">Kirikoshi 2009</LINK>; <LINK REF="STD-Lencioni-2010" TYPE="STUDY">Lencioni 2010</LINK>; <LINK REF="STD-Peng-2010" TYPE="STUDY">Peng 2010</LINK>; <LINK REF="STD-Pompili-2011" TYPE="STUDY">Pompili 2011</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>One trial had a low risk of bias (<LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>), while two trials had high risk of bias (<LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>; <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<ALLOCATION MODIFIED="2015-01-09 13:49:54 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="4">Random sequence generation</HEADING>
<P>Generation of the allocation sequence was done by computer randomisation in <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>, by random table in <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>, and was unclearly reported in <LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Allocation concealment was adequate in <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>, inadequate in <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>, and unclear in <LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>. In one trial, treatment groups were equalised in number of participants before the end of randomisation, but the number of participants was not stated (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>). In addition, six participants discontinued their foreseen therapy and were replaced by the next recruited participant without randomisation.</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2015-01-09 13:49:54 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We assumed that lack of blinding is unlikely to influence the assessment of objective efficacy outcomes such as survival. Moreover, as treatment modalities such as PEI and hepatic resection differ substantially concerning the degree of invasiveness, procedure performance, etc., reasonable blinding to the treatment of an investigator or an informed patient is unlikely. Regarding survival, all of the trials were therefore considered to have a low risk of bias. In contrast, quality events or outcomes such as tumour recurrence and adverse events were not blinded in any of the trials. Accordingly, we considered all trials to have high risk of bias regarding such outcomes.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-01-09 13:49:54 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>One trial gave reasons for withdrawals (<LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>), but not the other two trials. Two trials performed intention-to-treat analysis for all outcomes except for adverse events (<LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>; <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>), and one trial did not reported it (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-01-09 13:49:54 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We judged that the included trials were not biased by selective reporting. We retrieved relevant data for overall survival and recurrence-free survival from all trials.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-01-09 13:50:01 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We judged academic bias low in two trials (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>; <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>). Risk of academic bias was unclear in one trial (<LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>). Ohnishi et al. have published two retrospective trials on PEI for HCC previously (<LINK REF="REF-Ohnishi-1996a" TYPE="REFERENCE">Ohnishi 1996a</LINK>; <LINK REF="REF-Ohnishi-1996b" TYPE="REFERENCE">Ohnishi 1996b</LINK>). Lin et al. performed two randomised clinical trials during the same time period. People were assigned to one of the trials according to their hospital admission week (<LINK REF="REF-Lin-2004" TYPE="REFERENCE">Lin 2004</LINK>; <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>). However, we judged this low risk of bias.</P>
<P>Moreover, two trials included only treatment-naive participants (<LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>; <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>). Only two trials performed a sample size calculation (<LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>; <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>), whereas one trial mentioned no such calculation (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We found no eligible studies that compared PEI or PAI versus sham intervention, best supportive care, cryotherapy, laser-induced thermotherapy, or high-frequency ultrasound. We found no eligible trials that compared PAI with surgery.</P>
<SUBSECTION>
<HEADING LEVEL="3">Percutaneous ethanol injection versus percutaneous acetic acid injection</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for efficacy outcomes</HEADING>
<P>Two randomised trials compared PEI versus PAI and found that 31/91 participants treated with PEI and 19/94 participants treated with PAI died. There was no statistically significant difference between the two groups in overall survival (HR 1.47; 95% CI 0.68 to 3.19; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) or recurrence-free survival (HR 1.42; 95% CI 0.68 to 2.94; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) (<LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>; <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>). There were more deaths in the PEI group in the <LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK> trial than in the <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK> trial. There was heterogeneity for the trials (overall survival: Chi<SUP>2 </SUP>= 1.61 (P value = 0.21); I<SUP>2 </SUP>= 38%; recurrence-free survival: Chi<SUP>2 </SUP>= 3.43 (P value = 0.06); I<SUP>2 </SUP>= 71%).</P>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analyses</HEADING>
<P>We performed a subgroup analysis for the comparison PEI versus PAI that included the only low risk of bias trial (<LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>). There was no statistically significant difference for outcome overall survival (HR 1.13; 95% CI 0.63 to 2.03) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) or recurrence-free survival (HR 1.02; 95% CI 0.66 to 1.57) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Due to missing data, we could not perform subgroup analyses for the aetiology of liver cirrhosis or the diagnosis of HCC.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sensitivity analysis</HEADING>
<P>We did not conduct 'best-worst' and 'worst-best' sensitivity analyses due to paucity of data.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for safety outcomes</HEADING>
<P>Pain was the most frequent adverse event for people treated with PEI and PAI. The <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK> trial reported it as severe pain in 1/55 participants treated with PEI and in 3/58 participants treated with PAI. The <LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK> trial reported it as "pain" in '"most patients" in both groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for economic outcomes</HEADING>
<P>There were no data for economic outcomes. Only one trial reported the length of hospital stay (<LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>). <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK> reported a significantly shorter hospital stay from the beginning of therapy to dismissal of the participants treated with PEI (mean 1.7 days (range 2 to 3 days) versus PAI (mean 2.2 days (range 2 to 5 days); P value &lt; 0.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for quality of live</HEADING>
<P>None of the included trials collected data on quality of life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Risk of random error</HEADING>
<P>We calculated the diversity-adjusted required information size (DARIS) based upon a proportion of deaths of 23% in the PEI group; a relative risk reduction (RRR) of 20%; an alpha of 5% (&#945;) and a beta of 20% (ß). Trial sequential analysis with data from two trials that compared PEI with PAI found that (only) 185/2896 (6.3%) participants of the DARIS were accrued. The cumulative Z-score did not cross the monitoring boundary and did not reached the monitoring boundary for the area of futility (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Risk of bias</HEADING>
<P>We judged risk of bias low in one trial (<LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>), and high in the other trial due to the unclear random sequence generation (<LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). We did not create a funnel plot, as there were only two trials in the meta-analysis. We also did not perform a linear regression model analysis to determine funnel plot asymmetry for the same reason.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">GRADE assessment</HEADING>
<P>Evidence as evaluated by the GRADE approach (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) was low for the comparison of PEI versus PAI for overall survival, recurrence-free survival, and hospital stay (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Percutaneous ethanol injection versus surgery</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for efficacy outcomes</HEADING>
<P>One trial compared PEI with surgery for early HCC (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>). Three/38 participants treated with PEI and 5/38 participants treated with surgical resection died. Tumour recurrence occurred in 18/38 participants in the PEI group and 15/38 participants in the surgery group. There was no significant difference in overall survival (HR 1.57; 95% CI 0.53 to 4.61; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) or recurrence-free survival (HR 1.35; 95% CI 0.69 to 2.63; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for safety outcomes</HEADING>
<P>In the PEI versus surgery trial), 3/38 participants in the surgical group died within one, two, and seven months postoperatively (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>). These participants died from acute renal failure (at one month), sudden death (at two months), and uraemia (at seven months) (personal communication). In the PEI group, 2/38 participants had pain, and 1/38 participants had transient arterial hypotension (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>). The studies that were excluded for inadequate randomisation provided no additional report on adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for economic outcome</HEADING>
<P>
<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK> did not report any data on duration of hospital stay for either group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for quality of live</HEADING>
<P>
<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK> did not report any data on quality of life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Risk of random error</HEADING>
<P>As there was only one trial available, we could not apply trial sequential analysis. The trial did not perform a sample size calculation; therefore, we assumed a substantial risk of random error.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Risk of bias</HEADING>
<P>We judged the overall risk of bias of the one trial high due to the risk of pseudo-randomisation (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">GRADE assessment</HEADING>
<P>We assessed the evidence to be very low for the comparison of PEI versus surgery, as there was only one trial with a high risk of bias (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-01-19 11:42:08 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Percutaneous techniques are used with increasing frequency as a bridge to liver transplantation and with a curative intention for small HCC. We performed our first meta-analysis in 2009 in order to identify current evidence for the treatment of early HCC with PEI or PAI as compared to other treatment modalities (<LINK REF="REF-Schoppmeyer-2009" TYPE="REFERENCE">Schoppmeyer 2009</LINK>). Since this first review, no new trials were published. We found two new randomised trials on the ClinicalTrials.gov database. One trial compared PEI with surgical resection for early HCC (<LINK REF="STD-NCT00357474" TYPE="STUDY">NCT00357474</LINK>). The other trial compared PEI with transarterial chemoembolisation for multiple small HCCs (<LINK REF="STD-NCT00357422" TYPE="STUDY">NCT00357422</LINK>). Despite that these two trials are finalised, no results are published yet.</P>
<SUMMARY_OF_RESULTS MODIFIED="2015-01-19 11:42:08 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We found no significant difference regarding beneficial or harmful effects on median and recurrence-free survival of people with early-stage HCC, neither for treatment with PEI compared with PAI nor for treatment with PEI compared with surgical resection.</P>
<P>Resection, liver transplantation, and percutaneous treatments compete as first-line treatment options in people with early-stage HCC, defined according to the Milan criteria (<LINK REF="REF-Mazzaferro-1996" TYPE="REFERENCE">Mazzaferro 1996</LINK>), and well-preserved liver function. In these people, surgery yields a five-year-survival of 50% (<LINK REF="REF-Arii-2000" TYPE="REFERENCE">Arii 2000</LINK>; <LINK REF="REF-Bismuth-2000" TYPE="REFERENCE">Bismuth 2000</LINK>; <LINK REF="REF-Llovet--2000" TYPE="REFERENCE">Llovet 2000</LINK>). However, liver dysfunction as a consequence of underlying liver cirrhosis often limits surgical resection. Liver transplantation is hampered by the shortage of organ donors, which in turn can lead to progression of HCC while waiting for a new organ. Results of liver transplantation decline steeply with application of broader selection criteria due to high recurrence (<LINK REF="REF-Llovet--2000" TYPE="REFERENCE">Llovet 2000</LINK>). The most suitable candidates for transplantation are people with a single HCC nodule of 5 cm or less or up to three nodules of 3 cm or less who achieve low recurrence rates and a five-year survival of 70% (<LINK REF="REF-Mazzaferro-1996" TYPE="REFERENCE">Mazzaferro 1996</LINK>; <LINK REF="REF-Llovet--2000" TYPE="REFERENCE">Llovet 2000</LINK>). These so-called Milan criteria have been modestly expanded to a single nodule of 6.5 cm or less or up to three nodules of 4.5 cm or less, and a total tumour diameter of 8 cm or less (<LINK REF="REF-Yao-2002" TYPE="REFERENCE">Yao 2002</LINK>). The expanded criteria predict the survival after liver transplantation comparable to the more stringent Milan criteria (<LINK REF="REF-Yao-2002" TYPE="REFERENCE">Yao 2002</LINK>).</P>
<P>Local ablative therapies in early HCC have been developed since the 1980s. Treatment criteria for local ablative treatment resemble those in liver transplantation: one nodule of 5 cm or less or up to three nodules of 3 cm or less (<LINK REF="REF-Bruix-2001" TYPE="REFERENCE">Bruix 2001</LINK>). Image-guided, repeated PEI and PAI are procedures that can cause necrosis in small HCC but are safe and effective treatment modalities (<LINK REF="REF-Livraghi-1995" TYPE="REFERENCE">Livraghi 1995</LINK>; <LINK REF="REF-Lencioni-1997" TYPE="REFERENCE">Lencioni 1997</LINK>; <LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>).</P>
<P>We identified three trials that fulfilled the inclusion criteria of this systematic review. Only people with tumours of 3 cm or less were included in the three trials and most participants (242/261 participants) had liver cirrhosis. Two trials compared PEI versus PAI in early HCC (<LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>; <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>), and one trial assigned participants to undergo PEI versus surgical resection (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>). Two trials had a high risk of bias (<LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>; <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>), while one trial had a low risk of bias (<LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>). We found no randomised trials that compared local ablative therapy to no intervention or best supportive care or transplantation.</P>
<P>In people treated with PEI versus PAI, the median survival was not significantly different. There were no significant differences in recurrence-free survival. Both trials reported well-balanced participant groups with no striking differences in participants' characteristics between the trials except for aetiology of cirrhosis. Whereas 82% of participants had HCV-induced cirrhosis in the <LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK> trial, most participants had HBV-induced cirrhosis, and only 32% had HCV-induced cirrhosis in the <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK> trial. Both PEI and PAI were well tolerated. No severe adverse events were reported. The most frequent adverse event in both treatment modalities was pain, which was easily controlled with analgesics in most participants. Transient fever after both PEI and PAI and facial flushing following PEI were also observed. Duration of hospital stay and number of hospital admissions per year were each reported once (<LINK REF="STD-Ohnishi-1998b" TYPE="STUDY">Ohnishi 1998b</LINK>; <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>); hence, no firm conclusion can be drawn. However, the number of treatment sessions per tumour was consistently less with PAI than with PEI. Neither trial addressed quality of life.</P>
<P>For the comparison of PEI with surgical resection, the single retrieved trial found no significant difference regarding median survival and recurrence-free survival (<LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>). Pain was reported rarely in participants undergoing PEI and led to treatment discontinuation once. The authors specified no adverse events for surgical resection; however, three participants died postoperatively and were excluded from the authors' analysis of the trial. This and the flawed concealment procedure (equalising of participant number per trial group before the end of recruitment, non-randomised inclusion following exclusion of another participant) limits the value of this trial. The results of this trial concur with those of uncontrolled trials showing similar survival for participants treated with PEI compared to participants treated with segmental liver resection (<LINK REF="REF-Yamamoto-2001" TYPE="REFERENCE">Yamamoto 2001</LINK>). In clinical practice, the less invasive percutaneous treatment may be considered the preferable option.</P>
<P>RF(T)A is another well-established local ablative technique in early HCC. Available data from randomised clinical trials suggest that RFA is superior to injection therapies in terms of number of treatment sessions, recurrence-free survival, and overall survival (<LINK REF="REF-Lencioni-2003" TYPE="REFERENCE">Lencioni 2003</LINK>; <LINK REF="REF-Lin-2004" TYPE="REFERENCE">Lin 2004</LINK>; <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>; <LINK REF="REF-Shiina-2005" TYPE="REFERENCE">Shiina 2005</LINK>; <LINK REF="REF-Brunello-2008" TYPE="REFERENCE">Brunello 2008</LINK>). This is supported by one Cochrane systematic review from the Cochrane Hepato-Biliary Group (<LINK REF="REF-Weis-2013" TYPE="REFERENCE">Weis 2013</LINK>). However, RFA is associated with rare, but severe complications such as haemothorax and gastrointestinal perforation. Therefore, certain restrictions concerning location of the tumour in the liver apply to RFA. The practice guidelines of the European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) from 2012 recommend PEI only in people with early HCC in which RFA is technically not feasible. It is stated that it is unclear whether in people with very early HCC (tumours less than 2 cm, Barcelona Clinic Liver-Cancer (BCLC) 0) any of the two techniques can be used (<LINK REF="REF-EASL_x002d_EORTC-2012" TYPE="REFERENCE">EASL-EORTC 2012</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-01-09 13:51:06 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>What is the role that local ablative injection techniques may play in early HCC in the future? Because RFA is superior as compared with PEI regarding overall survival and tumour recurrence (<LINK REF="REF-Bouza-2009" TYPE="REFERENCE">Bouza 2009</LINK>; <LINK REF="REF-Cho-2009" TYPE="REFERENCE">Cho 2009</LINK>; <LINK REF="REF-Weis-2013" TYPE="REFERENCE">Weis 2013</LINK>), RFA should be preferentially used wherever it is available and small tumours are located within the range of that technique(i.e., not in the vicinity of larger vessels, the gallbladder, or the liver surface). In contrast, injection techniques may be used for their simplicity, safety, inexpensiveness, and wide availability in other instances.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-01-09 13:51:19 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Due to the small number of trials and participants included, the quality of evidence was low to very low. We conclude that the evidence does not allow a robust conclusion regarding the effects of PEI or PAI as compared to other interventions for early HCC. Moreover, we judged two of the three identified trials to have a high risk of bias.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-01-09 13:51:19 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We could not identify any potential bias in the review process.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-01-09 13:51:19 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Apart from our previous review (<LINK REF="REF-Schoppmeyer-2009" TYPE="REFERENCE">Schoppmeyer 2009</LINK>), we did not identify any reviews or meta-analyses that compared PEI versus PAI with other interventions excluding RFA for early HCC.</P>
<P>From a global perspective, HCC is a predominant cancer in the developing world with a much higher incidence than in industrialised countries. This is another potential setting for an effective and easy-to-manage local injection technique.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-01-19 10:47:02 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<IMPLICATIONS_PRACTICE MODIFIED="2015-01-09 13:51:19 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>On the basis of the limited evidence from the randomised clinical trials that we identified and included in this analysis, percutaneous ethanol injection (PEI) did not seem to differ from percutaneous acetic acid injection (PAI) regarding benefits and harms in people with one to three small (3 cm or less) HCC nodules. However, this evidence from two randomised trials was insufficient to guide the choice between PEI and PAI. This is also the case for the evidence for the comparison of PEI versus surgery for which we included only one trial.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-01-19 10:47:02 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Due to the risk of systematic errors (bias) and risk of random errors ('play of chance') as well as the limited number of participants studied, randomised clinical trials to assess the benefits and harms of local ablative interventions for people with small HCC should be conducted.</P>
<P>Furthermore, in intermediately progressed HCC (i.e., single nodule larger than 4 cm, more than four small nodules), no standard treatment has been sufficiently assessed. In particular, the role of combination therapies (e.g., transarterial chemoembolisation plus percutaneous local ablative therapy) in these tumours should be investigated in randomised trials. In addition, transarterial chemoembolisation itself is often applied in clinical practice, but we still lack large randomised trials or a conclusive meta-analysis that confirmed its effectiveness. Future trials should also address other clinically relevant aspects, such as number of treatment sessions, adverse events, and quality of life. The agreement on one optimal prognostically relevant staging system is important in order to make studies comparable. Another therapeutic interface that has not been well studied is the therapy to bridge the waiting time for people with HCC on the liver transplantation list. Randomised trials in this field are most awaited. Randomised trials ought to be designed according to the SPIRIT guidelines (Standard Protocol Items: Recommendations for Interventional Trials; <A HREF="http://www.spirit-statement.org">www.spirit-statement.org</A>) and reported according to the CONSORT guidelines (CONsolidated Standards of Reporting Trials; <A HREF="http://www.consort-statement.org">www.consort-statement.org</A>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-01-09 13:55:53 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We thank Hannelore Tenckhoff from the Kompetenznetz Hepatitis Ostdeutschland for her help with the bibliographic research and Dimitrinka Nikolova, Sarah Klingenberg, and Christian Gluud from the Cochrane Hepato-Biliary Group for their patience and ongoing support.</P>
<P>Peer reviewers: Ronald L. Koretz, USA; Alain Braillon, France.<BR/>Contact editor: Christian Gluud, Denmark.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-01-09 13:56:03 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Konrad Schoppmeyer and Sebastian Weis searched the literature, analysed the studies, prepared the protocol for the first meta-analysis and the update.<BR/>Annegret Franke advised and controlled the study analysis and updated the risk assessment. Annegret Franke also performed the GRADE evaluation and judged the quality of evidence.<BR/>Thomas Berg reviewed the literature, included the ongoing trials and with Joachim Mössner critically reviewed and updated the manuscript.<BR/>Wolfgang E. Fleig suggested the topic, accompanied the group during the whole reviewing and updating process, and reviewed the manuscript.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-01-09 13:55:32 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We did not search CancerLit as we did not expect to find further information.<BR/>First studies for PEI safety appeared in 1989. Therefore, meeting abstracts were searched starting 1989.<BR/>We changed the secondary outcomes: after obtaining statistical advice, we deleted the one-, two-, three-, and five-year survival and one-, two-, three-, and five-year recurrence-free-rates, as we did not expect to find any additional information.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2015-01-09 13:55:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Büchner-Steudel P, Behl S, and Fleig WE were the authors of the published protocol for the systematic review in Issue 3, 2002 of <I>The Cochrane Library</I>. Since the review could not be prepared on time, its protocol had to be withdrawn.<BR/>The author team changed again for the preparation of this and the last update. Authors are as follows: Weis S, Franke A, Berg T, Mössner J, Fleig WE, and Schoppmeyer K.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDIES MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<INCLUDED_STUDIES MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2005" MODIFIED="2008-12-18 11:12:48 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Huang 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-18 11:12:48 +0100" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang GT, Lee PH, Tsang YM, Lai MY, Yang PM, Hu RH, et al</AU>
<TI>Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study</TI>
<SO>Annals of Surgery</SO>
<YR>2005</YR>
<VL>242</VL>
<NO>1</NO>
<PG>36-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-09-07 22:49:36 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2005" MODIFIED="2008-12-18 11:13:47 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Lin 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-18 11:13:47 +0100" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC</AU>
<TI>Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less</TI>
<SO>Gut</SO>
<YR>2005</YR>
<VL>54</VL>
<NO>8</NO>
<PG>1151-6</PG>
<IDENTIFIERS MODIFIED="2008-10-22 23:01:16 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-22 22:10:02 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohnishi-1998b" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Ohnishi 1998b" YEAR="1998">
<REFERENCE MODIFIED="2009-05-12 15:33:21 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ohnishi K, Yoshioka H, Ito S, Fujiwara K</AU>
<TI>Prospective randomized controlled trial comparing percutaneous acetic acid and percutaneous ethanol injection for small hepatocellular carcinoma</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>1</NO>
<PG>67-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohnishi K</AU>
<TI>Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>1998</YR>
<VL>45</VL>
<PG>1254-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-09-07 22:19:03 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY DATA_SOURCE="PUB" ID="STD-Bottelli-1997" MODIFIED="2012-10-11 11:35:52 +0200" MODIFIED_BY="[Empty name]" NAME="Bottelli 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-10-11 11:35:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bottelli R, Iamoni G, Gelosa F, Caspani B, Cecconi P, Zavaglia C, et al</AU>
<TI>Interstitial laser photocoagulation (ILP) vs percutaneous ethanol injection (PEI) for treatment of hepatocellular carcinoma (HCC): preliminary results of a randomized pilot study [EASL abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<PG>S141</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruix-1998" MODIFIED="2008-12-18 11:14:54 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Bruix 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-12-18 11:14:54 +0100" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruix J, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MC, et al</AU>
<TI>Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>6</NO>
<PG>1578-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Danila-2009" MODIFIED="2012-10-11 11:37:54 +0200" MODIFIED_BY="[Empty name]" NAME="Danila 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-10-11 11:37:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Danila M, Sporea I, Sirli R, Popescu A</AU>
<TI>Percutaneous ethanol injection therapy in the treatment of hepatocarcinoma - results obtained from a series of 88 cases</TI>
<SO>Journal of Gastrointestinal and Liver Diseases</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>3</NO>
<PG>317-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dettmer-2006" MODIFIED="2008-12-18 11:16:25 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Dettmer 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-18 11:16:25 +0100" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dettmer A, Kirchhoff TD, Gebel M, Zender L, Malek NP, Panning B, et al</AU>
<TI>Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>23</NO>
<PG>3707-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huo-2002" MODIFIED="2008-12-18 11:16:51 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Huo 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-12-18 11:16:51 +0100" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huo TL, Huang YH, Wu JC, Lee PC, Chang FY, Lee SD</AU>
<TI>Survival benefit of cirrhotic patients with hepatocellular carcinoma treated by percutaneous ethanol injection as a salvage therapy</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>37</VL>
<NO>3</NO>
<PG>350-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huo-2003" MODIFIED="2015-01-01 21:46:20 +0100" MODIFIED_BY="Anne Lawson" NAME="Huo 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-01-01 21:46:20 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huo TI, Huang YH, Wu JC, Lee PC, Chang FY, Lee SD</AU>
<TI>Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>7</NO>
<PG>770-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huo-2004" MODIFIED="2008-12-18 11:17:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Huo 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-18 11:17:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huo T, Huang YH, Wu JC, Chiang JH, Lee PC, Chang FY, et al</AU>
<TI>Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>12</NO>
<PG>1301-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirikoshi-2009" MODIFIED="2012-10-11 11:40:38 +0200" MODIFIED_BY="[Empty name]" NAME="Kirikoshi 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-10-11 11:40:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirikoshi H, Saito S, Yoneda M, Fujita K, Mawatari H, Uchiyama T, et al</AU>
<TI>Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma</TI>
<SO>Hepatology Research</SO>
<YR>2009</YR>
<VL>39</VL>
<NO>6</NO>
<PG>553-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lencioni-2010" MODIFIED="2012-10-11 11:43:57 +0200" MODIFIED_BY="[Empty name]" NAME="Lencioni 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-10-11 11:43:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lencioni R, Crocetti L, Cioni D, Della Pina C, Oliveri F, De Simone P, et al</AU>
<TI>Single-session percutaneous ethanol ablation of early-stage hepatocellular carcinoma with a multipronged injection needle: results of a pilot clinical study</TI>
<SO>Journal of Vascular and Interventional Radiology</SO>
<YR>2010</YR>
<VL>21</VL>
<NO>10</NO>
<PG>1533-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orlando-1997" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Orlando 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orlando A, Cottone M, Virdone R, Parisi P, Sciarrino E, Maringhini A, et al</AU>
<TI>Treatment of small hepatocellular carcinoma associated with cirrhosis by percutaneous ethanol injection: a trial with a comparison group</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1997</YR>
<VL>32</VL>
<NO>6</NO>
<PG>598-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2010" MODIFIED="2012-10-11 11:46:54 +0200" MODIFIED_BY="[Empty name]" NAME="Peng 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-10-11 11:46:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peng ZW, Chen MS, Liang HH, Gao HJ, Zhang YJ, Li JQ, et al</AU>
<TI>A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma</TI>
<SO>European Journal of Surgical Oncology</SO>
<YR>2010</YR>
<VL>36</VL>
<NO>3</NO>
<PG>257-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pompili-2011" MODIFIED="2012-10-11 11:47:47 +0200" MODIFIED_BY="[Empty name]" NAME="Pompili 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-11 11:47:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pompili M, Nicolardi E, Abbate V, Miele L, Riccardi L, Covino M, et al</AU>
<TI>Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>26</NO>
<PG>3126-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sarin-1994" MODIFIED="2013-05-30 14:25:25 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Sarin 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-05-30 14:25:25 +0200" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sarin SK, Sreenivas DV, Saraya A, Mehta S, Lahoti D, Malhotra V</AU>
<TI>Improved survival with percutaneous ethanol injection in patients with large hepatocellular carcinoma</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>1994</YR>
<VL>6</VL>
<NO>11</NO>
<PG>999-1004</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-10-11 11:48:37 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Tsai-2008" MODIFIED="2012-10-11 11:48:37 +0200" MODIFIED_BY="[Empty name]" NAME="Tsai 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-10-11 11:48:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsai WL, Cheng JS, Lai KH, Lin CP, Lo GH, Hsu PI, et al</AU>
<TI>Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma - a long-term follow-up study</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>3</NO>
<PG>304-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00357422" MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="NCT00357422" YEAR="2005">
<REFERENCE MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00357422</AU>
<TI>Prospective randomized trial of the effective therapy for small, solitary HCC comparing operation and percutaneous ethanol injection therapy</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00357422</SO>
<YR>(accessed 7 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00357474" MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="NCT00357474" YEAR="2005">
<REFERENCE MODIFIED="2015-01-19 11:50:58 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00357474</AU>
<TI>A multicenter, randomized, controlled trial of the effective therapy for multiple, small hepatocellular carcinomas: comparing transarterial chemoembolization with percutaneous ethanol injection therapy</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00357474</SO>
<YR>(accessed 7 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-01-19 11:44:15 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ADDITIONAL_REFERENCES MODIFIED="2015-01-19 11:44:15 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<REFERENCE ID="REF-Abrishami-2008" MODIFIED="2013-05-30 14:41:31 +0200" MODIFIED_BY="[Empty name]" NAME="Abrishami 2008" TYPE="COCHRANE_PROTOCOL">
<AU>Abrishami A, Nasseri-Moghaddam S, Eghtesad B, Sherman M</AU>
<TI>Surgical resection for hepatocellular carcinoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-05-30 14:41:27 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-30 14:41:27 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006935"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arii-2000" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Arii 2000" TYPE="JOURNAL_ARTICLE">
<AU>Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al</AU>
<TI>Results of surgical and nonsurgical treatment for hepatocellular carcinomas: a retrospective and nationwide survey in Japan</TI>
<SO>Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>1224-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Awad-2009" MODIFIED="2013-05-30 14:42:42 +0200" MODIFIED_BY="[Empty name]" NAME="Awad 2009" TYPE="COCHRANE_REVIEW">
<AU>Awad T, Thorlund K, Gluud C</AU>
<TI>Cryotherapy for hepatocellular carcinoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-05-30 14:42:39 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-30 14:42:39 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007611.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Begg-1994" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Begg 1994" TYPE="JOURNAL_ARTICLE">
<AU>Begg CB, Mazumar M</AU>
<TI>Operating characteristics of a rank correlation test for publication bias</TI>
<SO>Biometrics</SO>
<YR>1994</YR>
<VL>50</VL>
<NO>4</NO>
<PG>1088-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bismuth-2000" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Bismuth 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bismuth H, Majno PE</AU>
<TI>Hepatobiliary surgery</TI>
<SO>Journal of Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>208-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bosch-2004" MODIFIED="2015-01-09 13:57:35 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Bosch 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bosch FX, Ribes J, Díaz M, Cléries R</AU>
<TI>Primary liver cancer: worldwide incidence and trends</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>127</VL>
<PG>S5-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bouza-2009" MODIFIED="2013-05-30 14:33:09 +0200" MODIFIED_BY="[Empty name]" NAME="Bouza 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bouza C, López-Cuadrado T, Alcázar R, Saz-Parkinson Z, Amate JM</AU>
<TI>Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma</TI>
<SO>BMC Gastroenterology</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>9</NO>
<PG>31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2008" MODIFIED="2013-05-29 15:10:31 +0200" MODIFIED_BY="[Empty name]" NAME="Brok 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Gluud C, Wetterslev J</AU>
<TI>Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<PG>763-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2009" MODIFIED="2015-01-09 13:58:49 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Brok 2009" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Wetterslev J, Gluud C</AU>
<TI>Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>287-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruix-2001" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Bruix 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al</AU>
<TI>Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference</TI>
<SO>Journal of Hepatology</SO>
<YR>2001</YR>
<VL>35</VL>
<PG>421-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brunello-2008" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Brunello 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al</AU>
<TI>Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2008</YR>
<VL>43</VL>
<NO>6</NO>
<PG>717-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calle-2003" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Calle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ</AU>
<TI>Overweight, obesity, and mortality of cancer in a prospectively studied cohort of U.S. adults</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>348</VL>
<PG>1625-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cho-2009" MODIFIED="2012-10-11 12:01:37 +0200" MODIFIED_BY="[Empty name]" NAME="Cho 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cho YK, Kim JK, Kim MY, Rhim H, Han JK</AU>
<TI>Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies</TI>
<SO>Hepatology</SO>
<YR>2009</YR>
<VL>49</VL>
<NO>2</NO>
<PG>453-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coleman-2003" MODIFIED="2014-11-27 16:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Coleman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Coleman MP, Gatta G, Verdeccia A, Esteve J, Sant M, Storm H, et al</AU>
<TI>EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century</TI>
<SO>Annals of Oncology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Suppl 5</NO>
<PG>V128-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CTU-2011" MODIFIED="2014-11-27 16:13:59 +0100" MODIFIED_BY="[Empty name]" NAME="CTU 2011" TYPE="OTHER">
<AU>Copenhagen Trial Unit</AU>
<TI>TSA - Trial Sequential Analysis</TI>
<SO>ctu.dk/tsa/</SO>
<YR>2011 (accessed 27 November 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EASL_x002d_EORTC-2012" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="EASL-EORTC 2012" TYPE="JOURNAL_ARTICLE">
<AU>European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer</AU>
<TI>EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma</TI>
<SO>Journal of Hepatology</SO>
<YR>2012</YR>
<VL>56</VL>
<NO>4</NO>
<PG>908-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analyses detected by a simple, graphical test</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El-Serag-1999" MODIFIED="2009-03-29 21:38:58 +0200" MODIFIED_BY="[Empty name]" NAME="El Serag 1999" TYPE="JOURNAL_ARTICLE">
<AU>El Serag HB, Mason AC</AU>
<TI>Rising incidence of hepatocellular carcinoma in the United States</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<PG>745-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El-Serag-2004a" MODIFIED="2015-01-02 23:08:42 +0100" MODIFIED_BY="Anne Lawson" NAME="El Serag 2004a" TYPE="JOURNAL_ARTICLE">
<AU>El-Serag H</AU>
<TI>Hepatocellular carcinoma: recent trends in the United States</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>127</VL>
<PG>S27-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El-Serag-2004b" MODIFIED="2015-01-02 23:08:37 +0100" MODIFIED_BY="Anne Lawson" NAME="El Serag 2004b" TYPE="JOURNAL_ARTICLE">
<AU>El Serag HB, Tran T, Everhart JE</AU>
<TI>Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>126</VL>
<PG>460-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galandi-2004" MODIFIED="2008-12-18 11:24:00 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Galandi 2004" TYPE="COCHRANE_REVIEW">
<AU>Galandi D, Antes G</AU>
<TI>Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-12-18 11:24:00 +0100" MODIFIED_BY="Sarah Louise Klingenberg">
<IDENTIFIER MODIFIED="2008-12-18 11:24:00 +0100" MODIFIED_BY="Sarah Louise Klingenberg" TYPE="DOI" VALUE="10.1002/14651858.CD003046.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2005" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Gluud 2005" TYPE="BOOK">
<AU>Gluud LL</AU>
<SO>Bias in Clinical Intervention Research [doctoral dissertation]</SO>
<YR>2005</YR>
<PB>Eget forlag</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2014" MODIFIED="2015-01-01 22:37:15 +0100" MODIFIED_BY="Anne Lawson" NAME="Gluud 2014" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al</AU>
<TI>Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<SO>2014, Issue 6. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heffernan-2002" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Heffernan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Heffernan N, Webster K, Odom L, Martone M, Passik S, Bookbinder M, et al</AU>
<TI>Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy - hepatobiliary questionnaire</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>9</NO>
<PG>2229-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2012-10-11 12:08:25 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>PA 19063-2043, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2009" MODIFIED="2014-07-14 14:08:38 +0200" MODIFIED_BY="[Empty name]" NAME="Lee 2009" TYPE="JOURNAL_ARTICLE">
<AU>Lee YC, Cohet C, Yang YC, Stayner L, Hashibe M, Straif K</AU>
<TI>Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<PG>1497-511</PG>
<IDENTIFIERS MODIFIED="2013-11-11 21:32:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lencioni-1997" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Lencioni 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lencioni R, Pinto F, Bassi AM, Moretti M, Di Giulio M, Marchi S, et al</AU>
<TI>Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: an European experience</TI>
<SO>European Radiology</SO>
<YR>1997</YR>
<VL>7</VL>
<PG>514-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lencioni-2003" MODIFIED="2008-12-18 11:11:00 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Lencioni 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al</AU>
<TI>Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection</TI>
<SO>Radiology</SO>
<YR>2003</YR>
<VL>228</VL>
<NO>1</NO>
<PG>235-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lin-2004" MODIFIED="2008-12-18 11:25:24 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Lin 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC</AU>
<TI>Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma &lt; or =4 cm</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>127</VL>
<NO>6</NO>
<PG>1714-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Livraghi-1995" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Livraghi 1995" TYPE="JOURNAL_ARTICLE">
<AU>Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolodi L, et al</AU>
<TI>Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection</TI>
<SO>Radiology</SO>
<YR>1995</YR>
<VL>197</VL>
<NO>1</NO>
<PG>101-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Llovet--2000" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Llovet  2000" TYPE="JOURNAL_ARTICLE">
<AU>Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, et al</AU>
<TI>Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma</TI>
<SO>Hepatology</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>54-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lundh-2012" MODIFIED="2013-05-29 14:54:04 +0200" MODIFIED_BY="[Empty name]" NAME="Lundh 2012" TYPE="COCHRANE_REVIEW">
<AU>Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L</AU>
<TI>Industry sponsorship and research outcome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>12</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.MR000033.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Macaskill-2001" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Macaskill 2001" TYPE="JOURNAL_ARTICLE">
<AU>Macaskill P, Walter SD, Irwing L</AU>
<TI>A comparison of methods to detect publication bias in meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>641-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Machin-1997" MODIFIED="2015-01-19 11:44:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Machin 1997" TYPE="JOURNAL_ARTICLE">
<AU>Machin D, Stenning SP, Parmar MK, Fayers PM, Girling DJ, Stephens RJ, et al</AU>
<TI>Thirty years of Medical Research Council randomized trials in solid tumours</TI>
<SO>Clinical Oncology</SO>
<YR>1997</YR>
<VL>9</VL>
<PG>100-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mazzaferro-1996" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Mazzaferro 1996" TYPE="JOURNAL_ARTICLE">
<AU>Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al</AU>
<TI>Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<PG>693-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohnishi-1996a" MODIFIED="2015-01-02 23:09:19 +0100" MODIFIED_BY="Anne Lawson" NAME="Ohnishi 1996a" TYPE="JOURNAL_ARTICLE">
<AU>Ohnishi K, Yoshioka H, Ito S, Fujiwara K</AU>
<TI>Treatment of nodular hepatocellular carcinoma larger than 3 cm with ultrasound-guided percutaneous acetic acid injection</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>24</VL>
<PG>1379-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohnishi-1996b" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Ohnishi 1996b" TYPE="JOURNAL_ARTICLE">
<AU>Ohnishi K, Nomura F, Ito S, Fujiwara K</AU>
<TI>Prognosis of small hepatocellular carcinoma (less than 3 cm) after percutaneous acetic acid injection: study of 91 cases</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>23</VL>
<PG>994-1002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohnishi-1998a" MODIFIED="2012-10-11 12:25:51 +0200" MODIFIED_BY="Sarah L Klingenberg" NAME="Ohnishi 1998a" TYPE="JOURNAL_ARTICLE">
<AU>Ohnishi K, Yoshioka H, Ito S, Fujiwara K</AU>
<TI>Prospective randomized controlled trial comparing percutaneous acetic acid and percutaneous ethanol injection for small hepatocellular carcinoma</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>1</NO>
<PG>67-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oliveri-2011" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Oliveri 2011" TYPE="COCHRANE_REVIEW">
<AU>Oliveri RS, Wetterslev J, Gluud C</AU>
<TI>Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-11-27 16:20:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-27 16:20:43 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004787.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parkin-2001" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Parkin 2001" TYPE="JOURNAL_ARTICLE">
<AU>Parkin DM, Bray F, Ferlay J, Pisani P</AU>
<TI>Estimating the world cancer burden: GLOBOCAN 2000</TI>
<SO>International Journal of Cancer</SO>
<YR>2001</YR>
<VL>94</VL>
<PG>153-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parkin-2005" MODIFIED="2008-12-18 11:27:13 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Parkin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Parkin DM, Bray F, Ferlay J, Pisani P</AU>
<TI>Global cancer statistics, 2002</TI>
<SO>CA: A Cancer Journal for Clinicians</SO>
<YR>2005</YR>
<VL>55</VL>
<NO>2</NO>
<PG>74-108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MKB, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-05-30 14:36:16 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ries-2007" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Ries 2007" TYPE="OTHER">
<AU>Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al</AU>
<TI>SEER cancer statistics, 2007</TI>
<SO>seer.cancer.gov/csr/1975_2001/</SO>
<YR>(accessed 14 July 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2009-03-18 10:56:00 +0100" MODIFIED_BY="[Empty name]" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovic-2012a" MODIFIED="2015-01-02 23:10:34 +0100" MODIFIED_BY="Anne Lawson" NAME="Savovic 2012a" TYPE="JOURNAL_ARTICLE">
<AU>Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Health Technology Assessment</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>35</NO>
<PG>1-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovic-2012b" MODIFIED="2015-01-02 23:10:29 +0100" MODIFIED_BY="Anne Lawson" NAME="Savovic 2012b" TYPE="JOURNAL_ARTICLE">
<AU>Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2012</YR>
<VL>157</VL>
<NO>6</NO>
<PG>429-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Serst_x00e9_-2012" MODIFIED="2013-11-26 15:07:26 +0100" MODIFIED_BY="[Empty name]" NAME="Sersté 2012" TYPE="JOURNAL_ARTICLE">
<AU>Sersté T, Barrau V, Ozenne V, Vullierme MP, Bedossa P, Farges O, et al</AU>
<TI>Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy</TI>
<SO>Hepatology</SO>
<YR>2012</YR>
<VL>55</VL>
<PG>800-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shiina-2005" MODIFIED="2008-12-18 11:31:52 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Shiina 2005" TYPE="JOURNAL_ARTICLE">
<AU>Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al</AU>
<TI>A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma</TI>
<SO>Gastroenterology</SO>
<YR>2005</YR>
<VL>129</VL>
<NO>1</NO>
<PG>122-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-S_x00f8_rensen-2003" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Sørensen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sørensen HT, Mellemkjær L, Jepsen P, Thulstrup AM, Baron J, Olsen JH, et al</AU>
<TI>Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2003</YR>
<VL>36</VL>
<PG>356-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takamori-2000" MODIFIED="2009-05-11 12:03:53 +0200" MODIFIED_BY="[Empty name]" NAME="Takamori 2000" TYPE="JOURNAL_ARTICLE">
<AU>Takamori R, Wong LL, Dang C, Wong L</AU>
<TI>Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary?</TI>
<SO>Liver Transplantation</SO>
<YR>2000</YR>
<VL>6</VL>
<PG>67-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2009" MODIFIED="2013-05-29 15:10:31 +0200" MODIFIED_BY="[Empty name]" NAME="Thorlund 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al</AU>
<TI>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>276-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2010" MODIFIED="2013-05-29 15:10:31 +0200" MODIFIED_BY="[Empty name]" NAME="Thorlund 2010" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Anema A, Mills E</AU>
<TI>Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals</TI>
<SO>Clinical Epidemiology</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>57-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual for Trial Sequential Analysis (TSA), 2011</TI>
<SO>ctu.dk/tsa/files/tsa_manual.pdf</SO>
<YR>2011 (accessed 14 July 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Torzilli-2013" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Torzilli 2013" TYPE="JOURNAL_ARTICLE">
<AU>Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al</AU>
<TI>A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West study group</TI>
<SO>Annals of Surgery</SO>
<YR>2013</YR>
<VL>257</VL>
<PG>929-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weis-2013" MODIFIED="2014-07-14 14:15:08 +0200" MODIFIED_BY="[Empty name]" NAME="Weis 2013" TYPE="COCHRANE_REVIEW">
<AU>Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K</AU>
<TI>Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2014-07-14 14:13:12 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-14 14:13:12 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003046.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2013-05-29 15:10:31 +0200" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2013-05-29 15:10:31 +0200" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in a random-effects meta-analysis</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2008-12-18 11:06:17 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yamamoto-2001" MODIFIED="2013-05-30 14:37:39 +0200" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Yamamoto 2001" TYPE="JOURNAL_ARTICLE">
<AU>Yamamoto J, Okada S, Shimada K, Okusaka T, Yamasaki S, Ueno H, et al</AU>
<TI>Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection</TI>
<SO>Hepatology</SO>
<YR>2001</YR>
<VL>34</VL>
<PG>707-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yao-2002" MODIFIED="2009-03-18 11:00:27 +0100" MODIFIED_BY="[Empty name]" NAME="Yao 2002" TYPE="JOURNAL_ARTICLE">
<AU>Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP</AU>
<TI>Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria</TI>
<SO>Liver Transplantation</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>9</NO>
<PG>765-74</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<REFERENCE ID="REF-Schoppmeyer-2009" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Schoppmeyer 2009" TYPE="COCHRANE_REVIEW">
<AU>Schoppmeyer K, Weis S, Mössner J, Fleig WE</AU>
<TI>Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-05-30 14:39:36 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-30 14:39:36 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006745.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-03-22 11:55:01 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Tsai-2008" MODIFIED="2009-05-13 11:15:53 +0200" MODIFIED_BY="[Empty name]" NAME="Tsai 2008" TYPE="JOURNAL_ARTICLE">
<AU>Tsai WL, Cheng JS, Lai KH, Lin CP, Lo GH, Hsu PI, et al</AU>
<TI>Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma - a long-term follow-up study</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>3</NO>
<PG>304-11</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-01-19 10:49:09 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-01-19 10:48:43 +0100" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Inclusion criteria" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Exclusion criteria" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Follow-up">
<INCLUDED_CHAR MODIFIED="2015-01-09 13:51:39 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Huang-2005">
<CHAR_METHODS MODIFIED="2014-08-05 04:55:09 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial.</P>
<P>Recruitment: August 1998 to December 2002.</P>
<P>Country: Taiwan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-09 13:51:39 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>76 participants: 38 PEI, 38 surgery.</P>
<P>No cirrhosis/Child A/Child B: PEI 6/29/3, surgery 10/28/0.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-09 13:51:39 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>PEI vs. surgery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-08 15:19:27 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Primary outcome: tumour recurrence.</P>
<P>Secondary outcome: overall survival.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-01-09 13:51:39 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>1 or 2 tumours each &#8804; 3 cm.</LI>
<LI>Location that allowed both treatment modalities.</LI>
<LI>Hepatitis without cirrhoses, Child A or B cirrhosis.</LI>
<LI>Platelet count &gt; 50,000/mm<SUP>3</SUP> or correctable by platelet transfusion.</LI>
<LI>PTT &lt; 5 seconds.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2015-01-09 13:51:39 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Any person who would not accept the selected treatment.</LI>
<LI>Any person with tumour recurrence.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-08 15:18:49 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>12 to 59 months.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-01-09 13:51:39 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>There were 2 participants switching from PEI to surgery despite the randomisation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:48:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Lin-2005">
<CHAR_METHODS MODIFIED="2014-07-02 13:48:41 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial.</P>
<P>Recruitment: April 2000 to June 2002.</P>
<P>Country: Taiwan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-09 13:51:59 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>187 participants: 62 RFTA, 62 PEI, 63 PAI.</P>
<P>Child A/Child B: RFTA 46/16, PEI 47/15, PAI 45/18.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:48:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>RFTA versus PEI versus PAI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-04 16:23:24 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome: local recurrence.</P>
<P>Secondary outcome: overall survival, cancer-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-01-09 13:51:59 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>1 to 3 HCC nodules each &#8804; 3 cm.</LI>
<LI>1-cm distance to hepatic hilum.</LI>
<LI>Absence of hepatic metastasis or vascular invasion.</LI>
<LI>Child A or B.</LI>
<LI>PTT &lt; 3 seconds, platelets &gt; 50,000/mm<SUP>3</SUP>.</LI>
<LI>No previous treatment.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2015-01-09 13:51:59 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Child C.</LI>
<LI>Previous HCC treatment.</LI>
<LI>Tumour located within 1 cm of the liver hilum or common bile duct.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-08 15:22:16 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>4 to 44 months.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-01-09 13:51:59 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>4.8% major complications in RFTA, 0% in the PAI and PEI groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:48:43 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Ohnishi-1998b">
<CHAR_METHODS MODIFIED="2014-07-02 13:48:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial.</P>
<P>Recruitment: August 1993 to September 1995.</P>
<P>Country: Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-09 13:52:15 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>60 participants: PEI 29, PAI 31.</P>
<P>Child A/Child B: PEI 21/8, PAI 20/11. 3 of 60 participants had chronic hepatitis without cirrhosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:48:43 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Total ethanol versus 50% acetic acid under US guidance.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-09 13:52:15 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Primary outcome: local recurrence.</P>
<P>Secondary outcome: overall survival, hospital admission, non-local recurrence, 1- and 2-year mortality, 1- and 2-year recurrence, 1- and 2-year cancer-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-01-09 13:52:15 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>1 to 4 tumours, each &#8804; 3 cm.</LI>
<LI>No previous HCC treatment.</LI>
<LI>Child A and B cirrhosis.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2009-05-09 22:10:19 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Child C cirrhosis.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-08 15:12:57 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>13 to 37 months.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-01-09 13:52:15 +0100" MODIFIED_BY="Dimitrinka Nikolova"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>HCC: hepatocellular carcinoma; PAI: percutaneous acetic acid injection; PEI: percutaneous ethanol injection; PTT: partial thromboplastin time; RFTA: radiofrequency thermal ablation.<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-01-09 13:52:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-01-09 13:52:38 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Bottelli-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 13:52:38 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Contact with the author was unsuccessful, not enough data retrievable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-08 15:11:53 +0100" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Bruix-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-08 15:11:53 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Advanced, not early HCC.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-02 23:40:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Danila-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-02 23:40:13 +0200" MODIFIED_BY="[Empty name]">
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-04 16:23:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dettmer-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-04 16:23:25 +0200" MODIFIED_BY="[Empty name]">
<P>Stratification in an interdisciplinary tumour-board instead of randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-08 15:12:07 +0100" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Huo-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-08 15:12:07 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Prospective, but not randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-24 23:26:46 +0200" MODIFIED_BY="Dimitrinka Koleva Nikolova" STUDY_ID="STD-Huo-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-24 23:26:46 +0200" MODIFIED_BY="Dimitrinka Koleva Nikolova">
<P>Quasi-randomised study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-09 13:52:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Huo-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 13:52:46 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Prospective survey, not randomised clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-02 23:44:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kirikoshi-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-02 23:44:18 +0200" MODIFIED_BY="[Empty name]">
<P>Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-09 13:52:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Lencioni-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 13:52:46 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-09 13:52:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Orlando-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 13:52:46 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Case-control study instead of prospective randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-09 13:52:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Peng-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 13:52:46 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-09 13:52:46 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Pompili-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-09 13:52:46 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Not a randomised clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-08 15:12:32 +0100" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Sarin-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-08 15:12:32 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Investigation of large HCC.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>HCC: hepatocellular carcinoma.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-01-19 10:48:55 +0100" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Inclusion criteria" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Exclusion criteria" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Follow-up">
<AWAITING_CHAR MODIFIED="2015-01-19 10:48:55 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Tsai-2008">
<CHAR_METHODS MODIFIED="2009-05-13 11:18:20 +0200" MODIFIED_BY="[Empty name]">
<P>Prospective randomised trial.</P>
<P>Recruitment: July 1998 to July 2004.</P>
<P>Country: Japan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-09 13:52:57 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>125 participants: 55 PEI, 70 PAI.</P>
<P>Child A/Child B-C: PEI 39/16 PAI 56/14.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:48:55 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>PEI versus PAI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-09 13:52:57 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Local tumour recurrence, new tumour recurrence, overall survival, cancer-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-01-09 13:52:57 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>1 to 3 tumours, each &#8804; 4 cm.</LI>
<LI>Tumours were unresectable or surgery refused.</LI>
<LI>INR &lt; 1.5, platelets &gt; 50,000/mm<SUP>3</SUP>.</LI>
<LI>No ascites.</LI>
<LI>No previous HCC treatment.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2015-01-09 13:52:57 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Previous HCC treatment.</LI>
<LI>Thrombosis of the portal vein.</LI>
<LI>Distant metastasis.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-01-09 13:52:57 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>2 to 110 months.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-01-09 13:52:57 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomisation was unclear. The authors reported a "...somewhat random manner by the operator...". Size of treatment groups differed strongly. People who were unresectable or did not agree to surgery were enrolled. No primary and secondary outcomes were determined, only outcomes in general. Contacting with the author was unsuccessful.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>HCC: hepatocellular carcinoma; PEI: percutaneous ethanol injection; INR: International Normalized Ratio; PAI: percutaneous acetic acid injection.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-01-19 10:49:09 +0100" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-01-19 10:49:04 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-NCT00357422">
<CHAR_STUDY_NAME MODIFIED="2015-01-09 13:53:11 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Multicenter, Randomized, Controlled Trial of the Effective Therapy for Multiple, Small HCCs: Comparing Transarterial Chemoembolization with Percutaneous Ethanol Injection Therapy.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-05-27 00:28:46 +0200" MODIFIED_BY="[Empty name]">
<P>Prospective randomised trial.</P>
<P>Country: Korea.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-09 13:53:11 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>284 participants.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:49:04 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>PEI versus TACE.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-09 13:53:11 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Primary outcome: overall survival.</P>
<P>Secondary outcome: disease-free survival, recurrence.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-05-27 00:29:54 +0200" MODIFIED_BY="[Empty name]">
<P>October 2005.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-01-09 13:53:11 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Yoon JH. Seoul National University Hospital.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Completed.</P>
<P>ClinicalTrials.gov identifier: <LINK REF="STD-NCT00357474" TYPE="STUDY">NCT00357474</LINK>.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-01-19 10:49:09 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-NCT00357474">
<CHAR_STUDY_NAME MODIFIED="2015-01-09 13:53:07 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Prospective Randomized Trial of the Effective Therapy for Small, Solitary HCC Comparing Operation and Percutaneous Ethanol Injection Therapy.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-05-27 00:18:15 +0200" MODIFIED_BY="[Empty name]">
<P>Prospective randomised trial.</P>
<P>Country: Korea.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-09 13:53:07 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Approximately 206 participants.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:49:09 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>PEI versus surgery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-09 13:53:08 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Primary outcome: overall survival.</P>
<P>Secondary outcome: disease -free survival, recurrence.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-05-27 00:16:55 +0200" MODIFIED_BY="[Empty name]">
<P>October 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-01-09 13:53:07 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Yoon JH. Seoul National University Hospital.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Completed.</P>
<P>ClinicalTrials.gov identifier: <LINK REF="STD-NCT00357422" TYPE="STUDY">NCT00357422</LINK>.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>HCC: hepatocellular carcinoma; PEI: percutaneous ethanol injection; TACE: transarterial chemoembolisation.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-01-09 13:52:33 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-01-09 13:52:20 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-21 16:22:05 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>Random table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-08 15:13:39 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Lin-2005">
<DESCRIPTION>
<P>Computer randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 13:52:20 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Ohnishi-1998b">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-01-09 13:52:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 13:51:50 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>Risk of pseudo-randomisation. The next enrolled participant who fulfilled inclusion criteria was assigned to the group from which a participant had just been excluded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-08 15:13:47 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Lin-2005">
<DESCRIPTION>
<P>List not available for treating physicians.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 13:52:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Ohnishi-1998b">
<DESCRIPTION>
<P>Sealed envelopes, but no information was given whether the envelopes were serially numbered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-01-09 13:52:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-09 13:51:50 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>Not described. Survival outcomes may not be significantly influenced by a lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-17 21:34:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005">
<DESCRIPTION>
<P>Not described. Survival outcomes may not be significantly influences by a lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-09 13:52:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Ohnishi-1998b">
<DESCRIPTION>
<P>Not described. Survival outcomes may not be significantly influenced by a lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-01-09 13:52:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-09 13:51:45 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>All drop-outs were properly reported and not included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-09 13:52:10 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Lin-2005">
<DESCRIPTION>
<P>There were no drop-outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-09 13:52:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Ohnishi-1998b">
<DESCRIPTION>
<P>There were no incomplete outcome data, no participant was withdrawn.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-01-09 13:52:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 13:51:50 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>We judged this trial free of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 13:52:10 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Lin-2005">
<DESCRIPTION>
<P>We judged this trial free of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 13:52:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Ohnishi-1998b">
<DESCRIPTION>
<P>We judged this trial free of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-01-09 13:51:50 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 13:51:50 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>The authors stated that prior to the enrolment, participants and doctors understood the protocol and suggested that this could have affected the person's decision to participate in the trial. In our opinion, understanding of the protocol is crucial for participation in all clinical trials for both participants and doctors.</P>
<P>People with tumour recurrence were treated by additional treatments, which could have approximated potential survival differences by the 2 compared modalities.</P>
<P>Groups were equalised in number before closure of randomisation. It was not stated how many participants were affected by this non-randomised measure.</P>
<P>Participants that did not complete their allocated treatment were displaced by the next recruited participant without randomisation (6 participants).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-08 15:14:07 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Lin-2005">
<DESCRIPTION>
<P>We did not detect any other potential bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-08 15:23:24 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Ohnishi-1998b">
<DESCRIPTION>
<P>We did not detect any other potential bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-05-24 01:01:44 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-05-24 01:01:44 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2015-01-09 13:52:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="10">
<NAME>Academic bias</NAME>
<DESCRIPTION>
<P>Was there any academic bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 13:51:54 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>There were no randomised clinical trials on this subject performed by this group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 13:52:10 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Lin-2005">
<DESCRIPTION>
<P>The same group performed another randomised clinical trial at the same time. Participants were assigned to 1 of the parallel trials depending on hospital admission during alternative weeks (<LINK REF="REF-Lin-2004" TYPE="REFERENCE">Lin 2004</LINK>). Previous retrospective trial on PEI for HCC.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 13:52:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Ohnishi-1998b">
<DESCRIPTION>
<P>The first author published at least 2 retrospective PAI analysis previously (<LINK REF="REF-Ohnishi-1996a" TYPE="REFERENCE">Ohnishi 1996a</LINK>; <LINK REF="REF-Ohnishi-1996b" TYPE="REFERENCE">Ohnishi 1996b</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2015-01-09 13:52:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="12">
<NAME>Overall risk assessment</NAME>
<DESCRIPTION>
<P>What ist the overall risk assessment of the trial?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 13:51:54 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>Due to the issues in other bias, we judged this trial high risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 22:02:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005">
<DESCRIPTION>
<P>Low risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-09 13:52:33 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="NO" STUDY_ID="STD-Ohnishi-1998b">
<DESCRIPTION>
<P>Due to the unclear random sequence generation, we judged this trial high risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-01-19 11:42:55 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-01-19 11:42:55 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2015-01-09 13:53:42 +0100" MODIFIED_BY="Dimitrinka Nikolova">Percutaneous ethanol injection (PEI) or percutaneous acetic acid injection (PAI) for early hepatocellular carcinoma (HCC)</TITLE>
<TABLE COLS="6" ROWS="16">
<TR>
<TD COLSPAN="6">
<P>
<B>PEI versus PAI or surgery for early HCC</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population: </B>hospitalised people with early HCC treated with PEI, PAI, or surgery.<BR/>
</P>
<P>
<B>Settings: </B>Taiwanese and Japanese university and adjunct teaching hospitals.<BR/>
<B>Intervention: </B>PEI.</P>
<P>
<B>Comparison: </B>PAI or surgery.</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Comparison</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>No. of</P>
<P>trials</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Hazard ratio<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>No. of participants<BR/>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER" COLSPAN="6">
<P/>
<P>
<I>
<B>PEI versus PAI </B>
</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Overall survival</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>PAI</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>
<B>HR 1.47 </B>
</P>
<P>(0.68 to 3.19)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>185</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;</P>
<P>
<B>low<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Recurrence-free survival</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>PAI</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>
<B>HR 1.42 </B>
</P>
<P>(0.68 to 2.94)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>185</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Number and type of adverse events </B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>PAI</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="3">
<P>Pain reported in both groups. Data not extractable for HR or OR.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Duration of hospital stay</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>PAI</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Mean</B>
</P>
<P>PAI: 2.2 days (range 2 to 5) versus PEI: 1.7 days (range 2 to 3)</P>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>125</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8853;&#8861;&#8861;&#8861;</P>
<P>
<B>very low<SUP>2</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>PAI</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="3">
<P>No data were provided.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" COLSPAN="6">
<P/>
<P>
<I>
<B>PEI versus surgery</B>
</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<B>Overall survival </B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Surgery</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>HR 1.57</B>
</P>
<P>(0.53 to 4.61)</P>
</TD>
<TD ALIGN="CENTER">
<P>76</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8853;&#8861;&#8861;&#8861;</P>
<P>
<B>very low<SUP>3</SUP>
</B>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT">
<P>
<B>Recurrence-free survival</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Surgery</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>HR 1.35 </B>
</P>
<P>(0.69 to 2.63)</P>
</TD>
<TD ALIGN="CENTER">
<P>76</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8853;&#8861;&#8861;&#8861;</P>
<P>
<B>very low<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Number and type of adverse events </B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Surgery</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>Insufficient amount of data provided.</P>
</TD>
<TD ALIGN="CENTER">
<P>76</P>
</TD>
<TD ALIGN="CENTER">
<P>&#8853;&#8861;&#8861;&#8861;</P>
<P>
<B>very low<SUP>4</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Duration of hospital stay</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Surgery</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="3">
<P>No data were provided.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Surgery</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="3">
<P>No data were provided.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
<P>
<B>CI:</B> confidence interval; <B>HR:</B> hazard ratio, <B>MD:</B> mean difference.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Graded as <I>low</I>, due to the risk of bias. Only one trial with low risk of bias was available and trial sequential analysis of both the high and low risk of bias trial revealed an insufficient number of included participants.<BR/>
<SUP>2</SUP> Graded as very <I>low</I>, as only one trial with low risk of bias was available.<BR/>
<SUP>3</SUP> Graded as <I>very low</I>, as only one trial of high risk of bias was available.<BR/>
<SUP>4</SUP> Graded as <I>very low</I>, as only one trial of high risk of bias was available and data presentation was not sufficiently precise.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2008-07-11 15:30:14 +0200" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<COMPARISON ID="CMP-001" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<NAME>Percutaneous ethanol injection (PEI) versus percutaneous acetic acid injection (PAI)</NAME>
<IV_OUTCOME CHI2="1.6055555555555554" CI_END="3.1861404663961954" CI_START="0.6794596982935891" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.471344296899456" ESTIMABLE="YES" I2="37.71626297577854" I2_Q="37.71626297577854" ID="CMP-001.01" LOG_CI_END="0.503264918494621" LOG_CI_START="-0.16783629805993291" LOG_DATA="YES" LOG_EFFECT_SIZE="0.167714310217344" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.20511773411784406" P_Q="0.20511773411784406" P_Z="0.3272709147275942" Q="1.6055555555555554" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.13624999999999995" TOTALS="YES" TOTAL_1="91" TOTAL_2="94" WEIGHT="100.0" Z="0.979625724434225">
<NAME>Overall survival: all trials</NAME>
<GROUP_LABEL_1>PEI</GROUP_LABEL_1>
<GROUP_LABEL_2>PAI</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PAI</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="2.029905408889771" CI_START="0.6262602901367198" DF="0" EFFECT_SIZE="1.1274968515793757" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.3074758007928469" LOG_CI_START="-0.20324512513606652" LOG_EFFECT_SIZE="0.05211533782839024" MODIFIED="2013-09-17 21:51:51 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6891565177502668" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="63" WEIGHT="68.68512110726644" Z="0.4">
<NAME>Low risk of bias trial</NAME>
<IV_DATA CI_END="2.029905408889771" CI_START="0.6262602901367198" EFFECT_SIZE="1.1274968515793757" ESTIMABLE="YES" ESTIMATE="0.12" LOG_CI_END="0.3074758007928469" LOG_CI_START="-0.20324512513606652" LOG_EFFECT_SIZE="0.05211533782839024" MODIFIED="2013-09-17 21:51:51 +0200" MODIFIED_BY="[Empty name]" ORDER="221" SE="0.3" STUDY_ID="STD-Lin-2005" TOTAL_1="62" TOTAL_2="63" WEIGHT="68.68512110726644"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="8.55040278096634" CI_START="0.8138506628164731" DF="0" EFFECT_SIZE="2.6379444593541526" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.9319865733750677" LOG_CI_START="-0.08945527848275923" LOG_EFFECT_SIZE="0.4212656474461543" MODIFIED="2013-09-17 21:51:56 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.10595025286811995" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="31.31487889273356" Z="1.6166666666666667">
<NAME>High risk of bias trial</NAME>
<IV_DATA CI_END="8.55040278096634" CI_START="0.8138506628164731" EFFECT_SIZE="2.6379444593541526" ESTIMABLE="YES" ESTIMATE="0.97" LOG_CI_END="0.9319865733750677" LOG_CI_START="-0.08945527848275923" LOG_EFFECT_SIZE="0.4212656474461543" MODIFIED="2013-09-17 21:51:56 +0200" MODIFIED_BY="[Empty name]" ORDER="220" SE="0.6" STUDY_ID="STD-Ohnishi-1998b" TOTAL_1="29" TOTAL_2="31" WEIGHT="31.31487889273356"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.429878048780488" CI_END="2.9444518680492795" CI_START="0.6841879099928446" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.4193513904862192" ESTIMABLE="YES" I2="70.84444444444445" I2_Q="70.84444444444445" ID="CMP-001.02" LOG_CI_END="0.46900445944989666" LOG_CI_START="-0.16482460432485907" LOG_DATA="YES" LOG_EFFECT_SIZE="0.15208992756251882" MODIFIED="2015-01-01 22:49:59 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.0640269309921292" P_Q="0.0640269309921292" P_Z="0.3469083213238533" Q="3.429878048780488" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.19925" TOTALS="YES" TOTAL_1="91" TOTAL_2="94" WEIGHT="99.99999999999999" Z="0.9406030662543909">
<NAME>Recurrence-free survival</NAME>
<GROUP_LABEL_1>PEI</GROUP_LABEL_1>
<GROUP_LABEL_2>PAI</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PAI</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="1.5701828485114042" CI_START="0.6628595995549934" DF="0" EFFECT_SIZE="1.0202013400267558" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.19595022914533333" LOG_CI_START="-0.17857844986920324" LOG_EFFECT_SIZE="0.008685889638065021" MODIFIED="2013-09-17 22:02:34 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.92756482661127" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="63" WEIGHT="55.97333333333332" Z="0.09090909090909091">
<NAME>Low risk of bias trial</NAME>
<IV_DATA CI_END="1.5701828485114042" CI_START="0.6628595995549934" EFFECT_SIZE="1.0202013400267558" ESTIMABLE="YES" ESTIMATE="0.02" LOG_CI_END="0.19595022914533333" LOG_CI_START="-0.17857844986920324" LOG_EFFECT_SIZE="0.008685889638065021" MODIFIED="2013-09-17 21:53:58 +0200" MODIFIED_BY="[Empty name]" ORDER="224" SE="0.22" STUDY_ID="STD-Lin-2005" TOTAL_1="62" TOTAL_2="63" WEIGHT="55.97333333333332"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="4.20547713191266" CI_START="1.109170285481177" DF="0" EFFECT_SIZE="2.159766253784915" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.623815275758555" LOG_CI_START="0.04499822637245285" LOG_EFFECT_SIZE="0.33440675106550394" MODIFIED="2013-09-17 22:02:34 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.023530734270600876" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="31" WEIGHT="44.026666666666664" Z="2.264705882352941">
<NAME>High risk of bias trial</NAME>
<IV_DATA CI_END="4.20547713191266" CI_START="1.109170285481177" EFFECT_SIZE="2.159766253784915" ESTIMABLE="YES" ESTIMATE="0.77" LOG_CI_END="0.623815275758555" LOG_CI_START="0.04499822637245285" LOG_EFFECT_SIZE="0.33440675106550394" MODIFIED="2013-09-17 21:54:05 +0200" MODIFIED_BY="[Empty name]" ORDER="225" SE="0.34" STUDY_ID="STD-Ohnishi-1998b" TOTAL_1="29" TOTAL_2="31" WEIGHT="44.026666666666664"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2">
<NAME>Percutaneous ethanol injection (PEI) versus surgery</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="4.608858403364752" CI_START="0.5336686215747671" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="1.5683121854901687" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.6635933656246341" LOG_CI_START="-0.27272833191170753" LOG_DATA="YES" LOG_EFFECT_SIZE="0.1954325168564633" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.41325338317986093" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="38" WEIGHT="100.0" Z="0.8181818181818181">
<NAME>Overall survival</NAME>
<GROUP_LABEL_1>PEI</GROUP_LABEL_1>
<GROUP_LABEL_2>Surgery</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours surgery</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="4.608858403364752" CI_START="0.5336686215747671" EFFECT_SIZE="1.5683121854901687" ESTIMABLE="YES" ESTIMATE="0.45" LOG_CI_END="0.6635933656246341" LOG_CI_START="-0.27272833191170753" LOG_EFFECT_SIZE="0.1954325168564633" MODIFIED="2008-10-31 13:36:17 +0100" MODIFIED_BY="[Empty name]" ORDER="15" SE="0.55" STUDY_ID="STD-Huang-2005" TOTAL_1="38" TOTAL_2="38" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="2.6284327466564394" CI_START="0.6932339443375064" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="1.3498588075760032" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.41969686926402666" LOG_CI_START="-0.1591201801220755" LOG_DATA="YES" LOG_EFFECT_SIZE="0.13028834457097557" MODIFIED="2015-01-09 13:59:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.3775859849688157" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="38" WEIGHT="100.0" Z="0.8823529411764705">
<NAME>Recurrence-free survival</NAME>
<GROUP_LABEL_1>PEI</GROUP_LABEL_1>
<GROUP_LABEL_2>Surgery</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours surgery</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.6284327466564394" CI_START="0.6932339443375064" EFFECT_SIZE="1.3498588075760032" ESTIMABLE="YES" ESTIMATE="0.3" LOG_CI_END="0.41969686926402666" LOG_CI_START="-0.1591201801220755" LOG_EFFECT_SIZE="0.13028834457097557" MODIFIED="2008-10-31 13:47:43 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SE="0.34" STUDY_ID="STD-Huang-2005" TOTAL_1="38" TOTAL_2="38" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-01-19 10:47:34 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-01-02 22:15:53 +0100" MODIFIED_BY="Anne Lawson" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAdUAAANhCAYAAACxfSG9AAB0QElEQVR42uydAYRVzf//v+SRJInk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-01-09 13:52:34 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies (survival outcomes).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAAEZCAMAAABy/dXVAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-01-09 13:52:34 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study (survival outcomes).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVoAAAF0CAIAAADtlWZnAAAS4klEQVR42u3dv24kRRDH8ZWQEIED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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Slide1.gif.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-01-19 10:47:34 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis for the comparison PEI versus PAI on survival in people with early hepatocellular carcinoma. The diversity-adjusted required information size (DARIS) was calculated based upon a proportion of deaths of 23% in the percutaneous ethanol injection (PEI) group; a relative risk reduction (RRR) of 20%; an alpha of 5% and a beta of 20%. The cumulative Z-score did not cross the monitoring boundary and did not reach the monitoring boundary for futility. Therefore, further randomised trials are needed.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtAAAAIcCAMAAADoo2lhAAADAFBMVEUAAAAAAADSAB0BAf8RAf8B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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-01-21 22:16:40 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2014-07-14 13:26:08 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-07-14 13:26:08 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-07-11 15:29:46 +0200" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-14 13:26:08 +0200" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Searched</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>July 2014</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(((ethanol or alcohol or acetic acid or vinegar) and (inject* or ablati*)) or PEI or PAI or PAAI) AND (((liver or hepatic or hepatocellular or hepato-cellular) and (carcinom* or cancer* or neoplasm* or malign* or tumo*)) or HCC)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Central Register of Controlled Trials (CENTRAL)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 6 of 12, 2014</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor: [Ethanol] explode all trees and with qualifier(s): [Administration &amp; dosage - AD, Therapeutic use - TU]</P>
<P>#2 MeSH descriptor: [Acetic Acid] explode all trees</P>
<P>#3 MeSH descriptor: [Injections] explode all trees</P>
<P>#4 (((ethanol or alcohol or acetic acid or vinegar) and (inject* or ablati*)) or PEI or PAI or PAAI)</P>
<P>#5 #1 or #2 or #3 or #4</P>
<P>#6 MeSH descriptor: [Liver Neoplasms] explode all trees</P>
<P>#7 (((liver or hepatic or hepatocellular or hepato-cellular) and (carcinom* or cancer* or neoplasm* or malign* or tumo*)) or HCC)</P>
<P>#8 #6 or #7</P>
<P>#9 #5 and #8</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1946 to July 2014</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 exp Ethanol/ad, tu [Administration &amp; Dosage, Therapeutic Use]</P>
<P>#2 exp Acetic Acid/ad, tu [Administration &amp; Dosage, Therapeutic Use]</P>
<P>#3 exp Injections/</P>
<P>#4 (((ethanol or alcohol or acetic acid or vinegar) and (inject* or ablati*)) or PEI or PAI or PAAI).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>#5 #1 or #2 or #3 or #4</P>
<P>#6 exp Liver Neoplasms/</P>
<P>#7 (((liver or hepatic or hepatocellular or hepato-cellular) and (carcinom* or cancer* or neoplasm* or malign* or tumo*)) or HCC).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>#8 #6 or #7</P>
<P>#9 #5 and #8</P>
<P>#10 (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>#11 #9 and #10</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1974 to July 2014</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 exp alcohol/ad, do, th [Drug Administration, Drug Dose, Therapy]</P>
<P>#2 exp acetic acid/ad, do, dt [Drug Administration, Drug Dose, Drug Therapy]</P>
<P>#3 exp injection/</P>
<P>#4 (((ethanol or alcohol or acetic acid or vinegar) and (inject* or ablati*)) or PEI or PAI or PAAI).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>#5 #1 or #2 or #3 or #4</P>
<P>#6 exp liver tumor/</P>
<P>#7 (((liver or hepatic or hepatocellular or hepato-cellular) and (carcinom* or cancer* or neoplasm* or malign* or tumo*)) or HCC).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>#8 #6 or #7</P>
<P>#9 #5 and #8</P>
<P>#10 (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>#11 #9 and #10</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index Expanded</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to July 2014</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 TS=(((ethanol or alcohol or acetic acid or vinegar) and (inject* or ablati*)) or PEI or PAI or PAAI)</P>
<P>#2 TS=(((liver or hepatic or hepatocellular or hepato-cellular) and (carcinom* or cancer* or neoplasm* or malign* or tumo*)) or HCC)</P>
<P>#3 #2 AND #1</P>
<P>#4 TS=(random* or blind* or placebo* or meta-analys*)</P>
<P>#5 #4 AND #3</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-01-21 22:16:40 +0100" MODIFIED_BY="[Empty name]">
<EXTENSION ID="AFF_35735DBF82E26AA200DA2AF314340255_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="35735DBF82E26AA200DA2AF314340255">
<ADDRESS>
<DEPARTMENT>Center for Sepsis Control and Care, and Center for Infectious Diseases and Infection Control</DEPARTMENT>
<ORGANISATION>Jena University Hospital</ORGANISATION>
<ADDRESS_1>Erlanger Allee 101</ADDRESS_1>
<ADDRESS_2/>
<CITY>Jena</CITY>
<ZIP>07747</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 trials included in primary analysis&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;5 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;18 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1784 records screened&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2381 records identified in total&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2379 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2 additional records identified through other sources (ongoing trials)&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;595 duplicates and 2 ongoing trials removed&lt;/p&gt;" WIDTH="140"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1766 records excluded&lt;/p&gt;" WIDTH="150"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;12 full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;1 article awaits classification due to insufficient information available&lt;/p&gt;" WIDTH="150"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 included study was excluded because of double publication&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="154"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 study excluded from primary analysis for pseudo-randomisation&lt;/p&gt;" WIDTH="188"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>